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The prevalence of Human immunodeficiency virus (HIV)/Acquired immune 
deficiency syndrome (AIDS) continues to increase worldwide, with HIV-1 subtype C 
being the most predominant subtype in South Africa. This study focused on cloning, 
expression and purification of HIV-1 subtype C Tat, Nef and RT proteins from 
recombinant Salmonella enterica serovar Typhimurium. The resultant purified Tat, 
Nef and RT proteins were used as antigens to investigate the prevalence of antibodies 
using Western blot analysis against HIV-1 subtype C Tat, Nef and RT proteins in 
sera of South African HIV-1 infected individuals sampled at different stages of 
disease. Serum samples from rhesus macaques vaccinated with candidate HIV-1 
vaccines (SAAVI DNA-C/C2 and SAAVI MVA-C) expressing HIV-1 subtype C 
proteins, Gag, RT, Tat, Nef and Env were also tested for HIV-1 antibody responses. 
 
HIV-1 tat, nef and rt genes were cloned into prokaryotic pGEM expression vector to 
construct pGEM+Tat, pGEM+Nef and pGEM+RT, respectively. The pGEM+Tat, 
pGEM+Nef and pGEM+RT were transformed into attenuated strain of Salmonella 
enterica serovar Typhimurium and recombinant Tat, Nef and RT proteins were 
extracted from the transformants. High levels expression of recombinant Tat, Nef 
and RT proteins were confirmed on SDS-PAGE gels Western blots. Purification of 
these proteins was a problem so the project was continued with His-tagged proteins. 
 
The recombinant Tat, Nef and RT proteins were purified from Salmonella enterica 
serovar Typhimurium transformed with plasmids contained HIV-1 tat, nef and rt 
genes in-frame with His-tag coding sequence. SDS-PAGE and Western blot showed 
that recombinant proteins were purified at high levels especially for Tat and Nef 
protein. The recombinant Tat and RT proteins could only be purified only under 
denaturing conditions because they are insoluble proteins and they can only purified 
as inclusion bodies by solubilizing with denaturant. Recombinant Nef protein is 
expressed as soluble protein and thus it was able to be purified under both denaturing 
and native conditions. However, the bulk of the Nef protein was expressed as 
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The purified Tat, Nef and RT recombinant proteins were used as antigens to 
investigate the prevalence of HIV-1 antibodies in sera of HIV-1 infected people. 
There was no reactivity in any of the 20 negative control sera in the Western blot 
assay. Analysis of 481 sera from HIV-1 infected individuals showed that the majority 
of serum samples had relatively high prevalence of anti-RT antibodies, ranging from 
89.9% to 95% irrespective of the clinical stages. Anti-Nef antibodies were observed 
in 47.4% of individuals tested and there was a strong association between the 
prevalence of these antibodies with the clinical stage of CD4 count range of 201 to 
499 cells/µl. The prevalence of anti-Tat antibodies was less frequent and only 7.5% 
of serum samples had anti-Tat antibodies. There was no association of anti-Tat and 
anti-RT antibodies with viral load or CD4 counts in sera of HIV-1 infected 
individuals. Altogether, 92% of serum samples tested had positive antibody 
responses to one or more antigens, indicating a good performance for the Western 
blot detection method.  
 
The prevalence of antibody response against purified HIV-1 subtype C antigens (Tat, 
Nef and RT) was also investigated in eleven sera of macaques vaccinated with 
SAAVI DNA-C or SAAVI-DNA-C2 and SAAVI MVA-C. Western blot assays 
showed that 36%, 27% and 40% of serum samples from vaccinated rhesus macaques 
had detectable antibodies against HIV-1 subtype C Tat, Nef and RT antigens, 
respectively. The prevalence of antibody responses to Tat, Nef and RT antigens in 
the sera of macaques is lower relative to the prevalence of antibody responses in the 
sera of HIV-1 infected individuals. A possible explanation is that the immune system 
of HIV-1 infected people is continuously exposed to viral antigens, thus resulting to 
high level of detectable anti- Tat, -Nef and -RT antibodies. In contrast, macaques 
were exposed to HIV-1 antigens expressed by the DNA and MVA vectors for only 
five times through vaccinations.  However, these results indicate that Western blot 
assay based on purified HIV-1 Tat, Nef and RT proteins may be a useful research 
tool for detection of antibody responses to corresponding vaccine immunogen in 
macaque sera. 
 
In conclusion, HIV-1 subtype C Tat, Nef and RT were successfully purified from 
Salmonella enterica serovar Typhimurium. The purified Tat, Nef and RT 
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RT antibodies in the sera of HIV-1 infected individuals and rhesus macaques 
vaccinated with candidate HIV-1 vaccines. Application of these purified proteins as 
reagents in a Western blot assay to detect antibodies in serum samples of HIV-1 
subtype C positive individuals demonstrated an association between the prevalence 
of anti-Nef antibodies and CD4 count range of 201 to 499 cells/µl. In addition, the 
detection of antibody responses to purified Tat, Nef and RT antigens in the sera of 
vaccinated macaques suggests a possible application of these purified proteins in 
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1 GENERAL INTRODUCTION 
Human immunodeficiency virus (HIV) was first identified in the early 1980s and has 
since been classified as one of the greatest health concerns globally (Barre-Sinoussi 
et al., 1983). HIV is member of the genus Lentivirus belonging to the family 
Retroviridae (Barre-Sinoussi et al., 1983). The virus is transmitted from one 
individual to another through blood or blood products (e.g blood transfusion) and 
unprotected sexual intercourse. HIV can also be transmitted through breast feeding in 
10% to 20% of exposed infants and through mother-to-child transmission during 
birth in 15% to 30% of children born by HIV-infected mothers who do not receive 
anti-retroviral drugs (Coovadial et al., 2007; Embree et al., 2000; Jiang et al., 2006). 
There are two types of HIV, namely HIV-1 and HIV-2. HIV-1 is the more 
pathogenic of the two types and is more common worldwide. HIV-1 infection in sub-
Saharan Africa is responsible for greater than 50% of HIV-1 infections worldwide 
(Heeney et al., 2006). HIV-1 and the simian immunodeficiency virus of chimpanzees 
(SIVcpz) share a common phylogenetic lineage, as HIV-1 originated from Western 
and Central African chimpanzees, Pan troglodytes troglodytes. HIV-2 is closely 
related to SIVmac and SIVsm that infect macaques and sooty mangabey monkeys, 
respectively (Rambaut et al., 2004). 
 
1.1  THE STRUCTURE AND REPLICATION OF HIV-1  
Two identical copies of a single stranded RNA of 9.5 kilobases (kb) is encapsidated 
in the HIV particle consisting of a capsid, matrix and envelope (Figure 1.1) (Muesing 
et al., 1987; Giri et al., 2004). At the virion surface there are envelope spikes with 
each spike representing a trimer of the two glycoproteins, gp120 and gp41 (Foster et 
al., 2001). Gp120 and gp41 are generated through proteolytic processing of the 
precursor gp160 and makes up the outer surface and the transmembrane envelope, 
respectively (Figure 1.1).  
 
During HIV infection, glycoprotein gp120 interacts with the host cell, CD4 receptor 
(Fig 1.2). This interaction causes the gp120 structure to undergo a conformational 
change and be able to bind either co-receptor CCR5 or CXCR4 depending on the 
virus. This subsequently results in fusion of the viral membrane with the membrane 
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reverse transcriptase converts RNA to double-stranded DNA. The virus encoded 
enzyme integrase, allows integration of the viral cDNA with the cells‟ own DNA 
(Peterlin and Trono, 2003). Division of the HIV infected cell leads to expression of 
viral genes. During the budding stage, the viral Gag and Gag-Pol polyproteins 
assemble at the cell membrane with the viral RNA and form immature virions. The 
pr55gag polyproteinis cleaved by the viral protease enzyme into the matrix, 
nucleocapsid and capsid proteins (Peterlin and Trono, 2003) resulting in the 
formation of mature HIV with a condensed core as illustrated in Figure 1.1. 
 
Figure 1.1: The structure of HIV (Giri et al., 2004). The structure shows structural 
components of the virus including matrix, capsid, nucleocapsid, viral enzymes (reverse 
transcriptase, protease, and integrase), and accessory proteins (Vpr, Vpu, Nef, p7, Rev and 
Tat), su: surface, tm: transmembrane. 
 
1.2  GENOME ORGANIZATION 
The HIV genome is made up of nine open reading frames encoding three groups of 
viral proteins and all are identified in Figure 1.3. Structural proteins are encoded by 
group antigen gene abbreviated as gag and env (envelope). The gag gene encodes 
p55 precursor of the matrix (MA, p17), capsid (CA, p24), nucleocapsid (NC, p7) and 
p6 protein. The env gene encodes the gp160/gp140 precursor of surface glycoprotein 
gp120 and transmembrane gp41 glycoprotein (Frankel and Young, 1998).  The pol 
gene encodes p64 and p53, which make up protease (p11), RT (reverse transcriptase; 
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activator) and Rev (regulator of virion expression) and they regulate the viral gene 
expression (Holguin et al., 2001; O‟Brien et al., 1997). Rev protein is a 13-19 kDa 
protein which allows transport of the late unspliced and partially spliced mRNA from 
the nucleus to the cytoplasm facilitating the expression of structural proteins (Pollard 
and Malim, 1998). Accessory proteins of HIV are also known as virulence factors 
and these proteins include Nef (Negative regulatory factor), Vif (Viral infectivity 
factor), Vpr (Viral protein), Vpu (Viral protein U, for HIV-1) or Vpx (Viral protein 
X, for HIV-2) (Piquet and Trono, 1999). These proteins enhance HIV-1 replication 
both in cell culture and in vivo (Kestler et al., 1991). This review will provide a 




Figure 1.2: The replicative cycle of HIV (Adapted from Peterlin and Trono, 2003). 
HIV-1 gp120 binds the human cell, CD4. The gp120-CD4 complex makes the gp120 
structure undergo conformational change allowing binding of CCR5 or CXCR4 which leads 
to viral fusion. The viral capsid is uncoated and enters the nucleus where reverse 
transcriptase convert ssRNA into dsDNA, The dsDNA is integrated and becomes provirus. 
Tat is expressed and increases the transcription level of the provirus. Rev transport spliced 
and unspliced genome transcripts from the nucleus to the cytoplasm where viral structural 
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Figure 1.3:  HIV-1 genomic organisation, transcripts and proteins (Peterlin and Trono, 
2003). The 10-kb viral genome contains open reading frame for 16 proteins, synthesised 
from at least ten transcripts. Black lines represent unspliced and spliced transcripts, above 
which coding sequences are given, with the start codons indicated. Above the encoding 
sequences, all singly spliced transcripts are shown. Tat requires Rev for their export from the 
nucleus to the cytoplasm. The RNA targets for Rev and the Rev response element (RRE) are 
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1.2.1 Tat Protein 
1.2.1.1 Structure of Tat protein 
The transcription activator (tat) protein binds to its response element located in the 
HIV-1 5‟ long terminal repeat (LTR) and is found in the nucleolus or nucleus (Bres 
et al., 2002; Jeang et al., 1999). It is usually expressed soon after viral infection in 
HIV infected patients (Wu and Marsh, 2001). Tat is a 14-16 kilodalton (kDa) protein 
encoded by the tat gene of the HIV-1 genome (Rana and Jeang, 1999) and it occurs 
as two isoforms: a smaller 14 kDa Tat protein encoded by the first exon and a full-
length 16 kDa protein encoded by the next two exons (Blazquez et al., 1999; 
Goldstein, 1996).  
 
The first exon, p14 is located in the central region of the viral genome and it encodes 
the 72 amino acids of Tat protein. Tat can be divided into amino terminal and basic 
domain regions and a cysteine rich region (aa 22-37) with 7 cysteines in 16 residues 
(Orsini et al., 1996). The amino (NH2) terminal domain (aa 1-21) is rich in proline 
and acidic residues and is essential for Tat function. A highly basic region is located 
at position 49-72 with 2 lysines and 6 arginine in 9 residues (Bres et al., 2002; Van 
Duyne et al., 2008; Vendeville et al., 2004). This region is important for nuclear 
localisation, facilitating the transport of Tat into the nucleus for binding to the 
transactivating response element (TAR) (Bres et al., 2002; Vendeville et al., 2004). 
TAR is a 55-nucleotide RNA stem loop structure located at the 5‟ end of HIV-1 
transcripts which acts to increase the level of viral transcription (Bres et al., 2002). 
 
The second exon, p16 encodes aa 73-86, and overlaps with the open reading frame of 
the envelope gene (Blazquez et al., 1999; Cui et al., 2004; Jeang et al., 1999). This 
exon encodes the extracellular matrix, carboxyl terminus (COOH) which is encoded 
by amino acids 14 to 32 and carries the highly conserved Arg-Gly-Asp (RGD) 
sequence (Blazquez et al., 1999; Chang et al., 1997). The RGD conserved region is 
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1.2.1.2 Functions of Tat protein 
Tat protein interacts with TAR by recruiting cyclin T1 and cyclin dependent kinase 
9, a complex that phosphorylates the carboxy-terminal domain of RNA polymerase 
II. This process stimulate the viral gene expression that promote HIV replication and 
transmission (Berkhout et al., 1989; Bres et al., 2005; Chang et al., 1994; Deng et 
al., 2000; Jones and Peterlin, 1994). The presence of Tat facilitates expression of 
structural genes (env, gag, and pol) in order for viral replication to proceed (Fisher et 
al., 1986). Although the virus is still able to infect CD4+ cells in the absence of Tat 
protein, it cannot undergo successive rounds of replication (Fisher et al., 1986; 
Richardson et al., 2003). This abortive replication occurs because Tat protein 
regulates efficient elongation of viral transcripts as well as viral infectivity by 
involving factors such as post transcription, transport of mRNA and translation (Feng 
and Holland, 1988; Peterlin et al., 1986). This process enhances the progression of 
AIDS disease (Richardson et al., 2003). 
 
1.2.1.3 Expression and purification of Tat protein 
Recombinant Tat protein has been produced in different expression systems 
including E. coli strains (Fanales-Belasio et al., 2002b; Larder et al., 1987; Ma et al., 
2006). The production of purified Tat protein has been achieved by using different 
purification techniques such as heparin-affinity chromatography and high 
performance liquid chromatography (HPLC) and affinity chromatography (Blázquez 
et al., 1999; Fanales-Belasio et al., 2002b; Ma et al., 2006; Park et al., 2002; Scheich 
et al., 2003). Due to the solubility of protein, Tat can be purified as inclusion bodies 
under denaturing conditions using urea. The protein yield of Tat protein may result in 
98% purity (Ma et al., 2006; Park et al., 2002). Tagging of Tat and other protein with 
His- and GST-tags is most commonly used and this process facilitates purification of 
proteins by affinity chromatography using Ni-NTA and glutathione agarose, 
respectively (Scheich et al., 2003). However, a study by Scheich et al., 2003 showed 
that His-tag fusion protein with Ni-NTA agarose produces higher yield of the 
purified protein compared to GST-tag using glutathione agarose. Using of GST-
tagged protein requires the use of glutathione agarose with reduced glutathione as it 
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1.2.1.4 Antibody responses to recombinant Tat antigen 
Tat protein is expressed soon after HIV infection before expression of structural 
genes and viral integration and plays a functional role in the viral life cycle (Ma et 
al., 1997; Jones and Peterlin, 1994). Recent studies conducted in Uganda and South 
Africa showed that immunogenic regions of Tat are well conserved among different 
HIV-1 subtypes particularly subtypes B and C (Butto et al., 2003; Fanales-Belasio et 
al., 2002a). A study by Butto et al. (2003) observed a prevalence of 50% of antibody 
responses to Tat protein in individuals with HIV-1 infection from Uganda. The 
persistence of anti-Tat antibodies in HIV-1 infected individuals is associated with 
slow progression of HIV-1 disease (Butto et al., 2003; Re et al., 2001; Richardson et 
al., 2003). 
 
In another study, Demirhan et al, (1999) used enzyme-linked immunosorbent assay 
(ELISA) to investigate the detection of antibodies to HIV-1 Tat in HIV-infected 
individuals with or without Kaposi‟s sarcoma (KS). Their results showed that 16% of 
individuals with HIV-1 and KS had anti-Tat IgG antibodies in their sera. However, 
no anti-Tat antibodies were observed in HIV-negative individuals and KS patients 
who were HIV-1 negative. This data suggests that the presence of Tat antibodies 
could be involved in pathophysiology of HIV-1 infection and may be associated with 
rapid disease progression (Demirhan et al., 1999), which is contrary to the findings 
of other studies (Belliard et al., 2003; Butto et al., 2003; Opi et al., 2002; Re et al., 
2001; Rezza et al., 2005; Richardson et al., 2003; Zagury et al., 1998).  
 
In a study to evaluate the prognostic value of anti-Tat antibodies, Rezza et al. (2005) 
used HIV-1 subtype B Tat protein to detect the presence of anti-Tat antibodies in the 
sera of HIV-1 infected patients. They found that 11.5% of the sera had anti-Tat 
antibodies. There was strong association of anti-Tat antibodies with slow disease 
progression (Rezza et al., 2005). HIV-1 infected patients with high level of anti-Tat 
antibodies showed long-term non-progression to AIDS compared to patients with 
low level of anti-Tat antibodies (Belliard et al., 2003; Butto et al., 2003; Opi et al., 
2002; Rezza et al., 2005; Richardson et al., 2003; Zagury et al., 1998). This finding 
was however, in opposition to the findings reported by Wieland et al. (1990) and 
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infected individuals had anti-Tat antibodies and this increased in patients with higher 
viral load and lower CD4 counts.   
 
The examples cited above illustrate that antibodies to Tat protein are present in the 
sera of HIV-1-infected individuals although they are variably detected in different 
populations. In addition, these studies drew differing conclusions regarding the 
association between the detection of anti-Tat antibodies and the rate of disease 
progression. It is possible that the different findings were the result of variable 
sensitivities and specificities of the methods of detection, suggesting that the 
detection of anti-Tat antibodies is dependent on the HIV-1 subtype from which the 
Tat protein was derived. Incorporating Tat protein derived from the HIV-1 subtype 
which is most prevalent in the target population in anti-Tat antibody detection may 
be expected to produce high performance of the detection method. Despite these 
findings, there is no similar information reported in regard to the detection of anti-
Tat antibodies in HIV-1 subtype C infected patients. Moreover, there is no clear 
evidence of association of the presence of anti-Tat antibodies with the disease 
progression in this population with subtype C infection. 
 
1.2.2 Nef Protein 
1.2.2.1 Structure of Nef protein 
The nef gene is located on the 3‟ end LTR of the viral RNA genome (Chaudhuri et 
al., 2007; Niederman et al., 1993). It encodes the 27 kDa Nef protein (also called 
Negative factor),  which is a negative regulatory factor of HIV-1 replication 
(Chaudhuri et al., 2007; Terwiliger et al., 1991; Walker et al., 2007). Nef is 
expressed at an early stage of HIV-1 infection (Arold and Baur, 2001; Klotman et al., 
1991). Unlike Nef of HIV-2 and SIV (250 amino acids long), HIV-1 Nef is slightly 
smaller in length of 206 amino acids (Niederman et al., 1993; Wei et al., 2003). Nef 
protein occurs as two isoforms; full-length myristylated amino terminal p27 protein 
and truncated p25 protein generated from the second start codon, so that it lacks the 
first 18 amino acids (Arold and Baur, 2001; Fackler et al., 1997). The p27 isoform is 
myristylated and as a result, it localises to the cellular membranes and is 
phosphorylated on serine and threonine residues. Due to the lack of myristylation of 
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1.2.2.2 Functions of Nef protein 
Nef protein plays an important role in the viral life cycle and pathogenesis of HIV 
and SIV infections in vivo through a number of ways (Moureau et al., 1999; Wei et 
al., 2003). Nef protein has been shown to down-regulate the HIV-1 receptors, CD4 
and CD28. This process prevents superinfection and promotes viral replication 
(Michel et al., 2005; Miller et al., 1994; Piquet et al., 1999; Wei et al., 2003). Nef 
protein also down-regulates the expression of MHC Class1 during early HIV 
infection and facilitates escape of infected cells from the Cytotoxic T-lymphocytes 
(CTL) response (Schnidler et al., 2006; Wei et al., 2003). Finally, Nef protein 
interacts with tyrosine and serine/threonine kinases to alter the activation state of 
cells leading to efficient proviral DNA synthesis and enhanced virion infectivity 
(Greenway et al., 2003; Linnemann et al., 2002; Piquet et al., 2003). HIV-1 Nef 
protein derived from subtypes B and C is highly immunogenic and well conserved. 
Both subtypes B and C have both B and T-cell epitopes which act to maintain viral 
function and fitness (Azad, 2000; Frahm et al., 2004; Masemola et al., 2004; 
Mashishi et al., 2001). 
 
1.2.2.3 Expression and purification of Nef protein 
Recombinant Nef protein has previously been produced in a variety of host cell 
systems such as E. coli cells, yeast, insect cells lines, plants (Tobacco Mosaic Virus), 
human and mammalian cells (Marusic et al., 2007; Moureau et al., 1999; 
Vermasvuori et al., 2009). Affinity chromatography using His- and GST-tag fusion 
protein, pseudoaffinity Cibacronble F3GA column and AcA54 gel-filtration column 
have been successfully used to obtain purified Nef proteins (Federico et al., 2001; 
Finzi et al., 2003; Wolber et al., 1992). Nef protein is very soluble and it can be 
purified at a high purity (95%) under both native and denaturing conditions using 
affinity chromatography (Federico et al., 2001; Finzi et al., 2003). However it has 
also been reported that production of this protein in E. coli can result in the formation 
of inclusion bodies which are cytoplasmic aggregates that represent the presence of 
misfolded protein (Vermasvuori et al., 2009).  However, despite the disadvantages of 
E.coli production which include lack of secretion of the Nef protein, Nef being found 
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other proteins E.coli production was still more efficient and cost effective than 
production in yeast or insct cells (Vermasvuori et al., 2009). 
 
1.2.2.4 Antibody responses to recombinant Nef antigen 
 
As mentioned earlier, Nef is expressed at an early stage during the HIV life cycle and 
plays an important role in the pathogenesis of HIV (Fuji et al., 1996; Otake et al., 
1994). Bahraoui et al, (1990) investigated whether detection of anti-Nef antibodies 
can serve as an early marker of HIV infection. HIV-1 Nef derived from subtype B 
(LAV Bru Strain) was expressed and purified from E. coli by ultra filtration. Purified 
Nef protein was used to investigate the prevalence of anti-Nef antibodies in the sera 
of HIV-1 infected patients using radioimmunoassay (RIA), Western blot and ELISA 
(Bahraoui et al., 1990). It was found that 30% to 70% of the sera sampled from HIV-
1 infected patients with various CD4 counts had anti-Nef antibodies. These results 
indicated that the presence and/or detection of anti-Nef antibodies were not 
consistent enough to be used as an early marker of HIV infection (Bahraoui et al., 
1990).  
Chen et al. (1999) investigated the correlation of anti-Nef antibody with AIDS 
disease progression. They conducted a follow up study on sera obtained from 174 
HIV-1/ AIDS patients before and after they received 1 year of anti-retroviral 
treatment. This study employed a Western blot assay with purified recombinant Nef 
protein and showed that 77% of the sera had anti-Nef antibodies. Chen et al. (1999) 
further showed that 21.1% of patients who initially showed no anti-Nef antibody 
response seroconverted (conversion of negative response to positive response) while 
7.2% of patients who were positive to anti-Nef antibodies seroreverted (the reversion 
of positive response to negative response). This was an expected outcome due to 
anti-retroviral treatment. A high percentage of anti-Nef antibodies in the sera from 
HIV-1 infected patients regardless of their clinical stage has also been reported and it 
was strongly associated with slow disease progression (Wieland et al., 1990). The 
above studies used sera from HIV-1 subtype B infected individual. Similar studies 
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1.2.3 Reverse Transcriptase (RT) protein 
1.2.3.1 Structure of RT protein 
HIV-1 RT protein is encoded by the pol gene (Hang et al., 2004). RT is a 
heterodimer protein composed of two subunits; a 66 kDa subunit (p66) having 560 
amino acids and a 51 kDa subunit (p51) with 440 amino acids (Sluis-Cremer et al., 
2004). The p51 subunit is generated from p66 through proteolytic cleavage and lacks 
the ribonuclease H (RNase H) domain (di Marzo Veronese et al., 1986). The p66 
subunit has RNase H activity located within a domain of 120 amino acids that 
catalyses the degradation of the RNA strand of RNA/DNA hybrids (Hang et al., 
2004; Telesnitsky and Goff, 1997). Both p66 and p51 subunits have the polymerase 
domains although the polymerase active site in the p51 subunit is not functionally 
active (Wang et al., 1994). The p66 protein dimerises to produce p66/p66 
homodimers that display DNA polymerase and RNase H activities (Restle et al., 
1992). RT is composed of the DNA-binding cleft formed by four domains in both 
p51 and p66 subdomains (Figure 1.4). These include fingers, thumb, palm and 
connection (Jonckheere et al., 2000; Sarafi nso et al., 2002). However, the p66 
subdomain also has carboxyl terminal RNase H that serves as the fifth domain 
(Huang et al, 1998). The connection and palm domains are individually composed of 
three beta sheets with alpha helices and are important for the DNA polymerase 
catalytic activity (Frankel and Young, 1998). The thumb subdomain is composed of 
three alpha helices (Jonckheere et al., 2000; Sarafianso et al., 2002). The finger and 
thumb subdomains describe a deep cleft and are important for the polymerase active 
site of the p66 subunit which is defined by three catalytic aspartic acid residues 
(Asp110, Asp185, Asp186) that may play a role in binding metal ions (Frankel and 
Young, 1998; Olivares et al., 1999). 
 
1.2.3.2 Function of RT protein 
RT transcribes single-stranded viral RNA template into double-stranded DNA 
through reverse transcription (Havlir et al., 1996; Mitsuya, et al., 1990). This process 
is carried out by the active site of subunit p66 and is essential for HIV propagation 
(Havlir et al., 1996; Mitsuya, et al., 1990). The process of reverse transcription is 
error-prone and it leads to high viral mutation rate that can confer drug resistance 
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catalyses the degradation of the RNA strand of RNA/DNA hybrids required for 
reverse transcription (Hang et al., 2004). The p51 domain acts as the binding site for 
the anti-codon and loop of tRNAs that serve as primers for the synthesis of the DNA 
template (Frankel and Young, 1998).  
 
 
Figure 1.4:  The thre  dimensional structure of HIV-1 RT protein (Adapted from 
Jonckheere et al., 2000). The blue colour represents finger domains, yellow represents 
thumb domains, green represents palm domains, red represents the connections and purple 
represents RNaseH domains.  
 
1.2.3.3 Expression and purification of RT protein 
RT protein has been produced in E. coli using prokaryotic expression vectors 
(Fletcher et al., 1996). The RT protein has been purified with SP-Sepharose, Affi-
Gel Blue columns and with and/or without His-tag label by affinity chromatography 
(Fletcher et al., 1996; Grüninger-Leitch, 1990; Hou et al., 2004). RT protein is 
expressed as insoluble bodies and it can only be purified under denaturing conditions 
by solubilisation with urea (Rudolph and Lilie, 1996; Vallejo and Rinas, 2004). RT 
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phenylmethanesulphonylfluoride (PMSF) during purification may aid in preventing 
the proteolytic degradation (Rudolph and Lilie, 1996).  
 
1.2.3.4 Antibody responses to recombinant RT antigen 
RT protein is routinely incorporated in screening and diagnostic tests. However, only 
few studies have reported on anti-RT antibodies in the sera of HIV infected 
individuals. RT is produced early in the life-cycle of HIV-1 infection and it catalyses 
reverse transcription of RNA into DNA to promote viral replication (Havlir et al., 
1996; Mitsuya, et al., 1990).  
RT protein is highly immunogenic and it is consistently detected in the sera of HIV-1 
infected patients irrespective of the clinical status (di Marzo-Veronese et al., 1986). 
Using Western blot assay, 700 sera from HIV-1 subtype B infected individuals were 
tested for the prevalence of antibodies to RT (p66) in three different stages 
(asymptomatic, AIDS related complex (ARC) and AIDS) of the disease (DeVico et 
al., 1988). Nearly 80% of the sera had anti-RT antibodies regardless of the clinical 
stages of the disease (DeVico et al., 1988). 
  
In another study, Odawara et al. (1996) used a non-radioisotopic reverse 
transcriptase assay to investigate the prevalence of anti-RT antibodies in the sera of 
HIV-1 subtype B infected individuals. Their results showed that 83.6% of the sera 
tested had anti-RT antibodies. The prevalence of anti-RT antibodies was associated 
with slow disease progression in HIV infected patients (Odawara et al., 1996). This 
was also shown by the high prevalence of anti-RT antibodies that protected HIV-1 
infected individuals and reduced disease progression through inhibition of RT 
enzymatic activity (Jonckheer et al., 2000; Laurance et al., 1987).  
 
1.3 HIV VACCINES 
1.3.1 HIV vaccine pre-clinical development 
The development of an HIV vaccine involves three general stages: discovery, pre-
clinical development and clinical trials. Prior to clinical development, a vaccine must 
satisfy basic requirements to ensure safety and immunogenicity. Initial 
immunogenicity is tested in small animals such as mice and guinea pigs (McCune, 
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species such as chimpanzees and macaques (cynomolgus, rhesus and pig-tailed) 
(Joag et al., 2000; Kahn et al., 1998; Li et al., 2000). Non-human primates share 
many immunological characteristics (MHC antigens, T-cell receptors antigens, 
molecularly and biologically cytokines) with humans, making them the most suitable 
animal models for HIV studies (Joag et al., 2000; Li et al., 1992; van Maanen and 
Sutton, 2003). Among these species, only chimpanzees can be infected with HIV and 
were thus preferred as the most suitable model for HIV studies. There are however, 
disadvantages of working with chimpanzees because they rarely show AIDS 
symptoms, they are scarce and endangered species, and it is very expensive to work 
with them (Gardner et al., 1990; Li et al., 1992; van Maanen and Sutton, 2003). 
Instead, macaques are being used since they can acquire a disease similar to AIDS 
when they are infected with SIV or when infected with recombinant SHIV (Mäkitalo 
et al., 2004). SHIV is a combination of HIV and SIV which mimics HIV infection 
(Mäkitalo et al., 2004). However, monkeys challenged with SHIV (SHIV89.6P) 
progress to disease faster than most humans which is why this strain is no longer 
used (Reimann et al., 1996). Another limitation of using monkey models is the fact 
that the vaccines must be modified so that they carry SIV genes (Li et al., 1992).   
 
1.3.2 HIV vaccine strategies 
Many different vaccine strategies are currently applied for the development of HIV 
vaccines. These strategies included using recombinant subunit, viral vector and DNA 
vaccines as vaccine delivery systems (Fernandez-Cruz et al., 2003; Ohmit et al., 
2008; Whatmore et al., 1995). For other human viruses such as polio, hepatitis A, 
rabies and influenza whole inactivated and live attenuated vaccines are the most 
common and successful vaccines (Fernandez-Cruz et al., 2003). Live-attenuated 
vaccines include measles, rubella, polio and chicken pox (Daniel et al., 1992; 
Whatmore et al., 1995). A possible complication associated with whole inactivated 
and live attenuated vaccines is their possible reversion to a virulent form as shown 
previously (Daniel et al., 1992; Ohmit et al., 2008; Whatmore et al., 1995).  This is 
of particular concern with HIV because of the high mutation rate making these 
strategies too risky. Recombinant subunit vaccines are vaccines that use a specific 
purified antigen separated from virulent organism. These vaccines are being used 










Page | 27 
 
et al., 2008). Although, subunit vaccines can be used to avoid risks associated with 
live attenuated and whole killed vaccines, they mainly elicit antibody responses and 
weak cell-mediated responses (Schellenbacher et al., 2009; Schiller et al., 2008). 
DNA vaccines have also been developed as HIV vaccines and they involve cloning 
of the desired gene into the bacterial plasmid (Castaldello et al., 2006; Darrah et al., 
2007; Kumer et al., 2006; Robinson et al., 2006). DNA based vaccines have been 
used in combination with subunit and viral vector vaccines for HIV studies. They 
have the ability to elicit robust CD8+ T cell responses (Castaldello et al., 2006; 
Darrah et al., 2007; Kumer et al., 2006; Robinson et al., 2006).  
  
1.3.2.1 Viral vectors 
Viral vectors are used to deliver vaccine antigens to antigen-presenting cells (APC) 
(Catanzaro et al., 2006). Their most attractive feature is that they can induce 
antibody responses and cell mediated responses (CD8+ and CD4+) to recombinant 
antigens. Adenovirus 5 (replication-defective recombinant vector), ALVAC (derived 
from canarypox virus) and Modified Vaccinia virus Ankara (MVA) are good 
examples of such vectors and they have been used in several HIV studies (Catanzaro 
et al., 2006; Mwau et al., 2004; Sandström et al., 2006; Trinvuthipong et al., 2004). 
These viral vectors can be used together and in combination with DNA vaccine 
vectors to boost immune responses and this process is known as heterologous prime-
boost immunization (explained in detail in Chapter 5). The current study focuses on 
plasmid DNA vaccines boosted with MVA viral vector. 
 
1.3.2.1.1 Modified Vaccinia virus Ankara (MVA) 
MVA is an attenuated viral vector derived from Vaccinia virus (Hanke et al., 2005; 
Seth et al., 1998).  It has been used as a vaccine for small pox (Hanke et al., 2005). 
MVA has been used as an HIV vaccine vector in various animal models because of 
its ability to express high levels of foreign antigen and accept large inserts as well as 
its safety profile for use in humans (Cosma et al., 2003; Meyer et al., 1991; Ramirez 
et al., 2000; Stittelaar et al., 2002).  
 
Hanke et al. (2005) demonstrated that MVA has the ability to induce robust of 
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with recombinant MVA expressing influenza virus haemagglutinin and 
nucleoprotein genes (Sutter et al., 1994). In another study, Hirsch et al. (1996) 
compared the immunogenicity and protective efficacy of MVA-SIV and Wyeth-SIV 
(replication competent vaccinia strains) vaccines expressing SIVsm gag-pol in 
vaccinated macaques. Broad immune responses to Env and Gag-Pol proteins were 
detectable in MVA-SIV vaccinated macaques whereas vaccination with Wyeth-SIV 
resulted in low levels of vaccinia virus and SIV neutralising antibodies.  The MVA-
SIV vaccine prevented SIV infection in vaccinated macaques whereas the Wyeth-
SIV vaccine did not (Hirsch et al., 1996).  
 
Recent study made in South Africa, showed that DNA and MVA vaccines expressing 
HIV-1 subtype C multigene polyprotein was highly immunogenic and generated high 
levels of HIV-specific CD4+ and CD8+ cells in mice, guinea pigs and baboons 
(Shephard et al., 2008; Burgers et al., 2008 & 2009). Similar results were obtained in 
rhesus macaques vaccinated with same vaccines (unpublished data). All the above 
examples indicated that MVA improves the immune response in animal models. 
 
1.4 OVERALL OBJECTIVES OF THE PROJECT 
HIV-1 Tat, Nef and RT proteins can be used to detect specific antibodies in the sera 
of HIV-1 infected patients. Previous studies showed that antibodies to HIV-1 Tat, 
Nef and RT were detectable in sera of HIV-1 subtype B infected patients at various 
quantities. Thus, this study aimed to clone, express and purify HIV-1 subtype C Tat, 
Nef and RT proteins. The first antibody study was performed using purified Tat, Nef 
and RT as antigens to investigate the prevalence of the antibody responses in the sera 
of HIV-1 subtype C infected patients. The second part of this thesis tested for 
antibodies in non-human primates vaccinated with two vaccines, funded by South 
African AIDS Vaccine Initiative (SAAVI). Therefore the sera from macaques 
vaccinated with the SAAVI DNA-C/C2 vaccine and boosted with SAAVI MVA-C 
were also tested for antibodies to Tat, Nef and RT.  
 
 The specific objectives of the project were:  
 To clone and express HIV-1 subtype C Tat, Nef and RT proteins in Salmonella 










Page | 29 
 
 
 To purify His-tagged HIV-1 subtype C Tat, Nef and RT proteins from 
Salmonella enterica serovar Typhimurium for Western blotting (Chapter 3).  
 
 To investigate the prevalence of HIV-1 Tat, Nef and RT antibodies in the sera of 
HIV-1 infected individuals as detected by Western blot (Chapter 4). 
 
 To investigate whether there is an association between the prevalence of these 
antibodies and the clinical stage of AIDS disease (as categorized by CD4+ T cell 
count and plasma viral load) (Chapter 4)  
 
 To investigate the prevalence of HIV-1 Tat, Nef and RT antibodies in the sera of 
macaques vaccinated with SAAVI-DNA and SAAVI-MVA expressing HIV-1 
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2.1 INTRODUCTION 
The genus Salmonella is made up of rod-shaped, gram-negative enterica bacteria that 
belong to the Enterobacteriaceae family (Miller et al., 1995; Chang et al., 1997b). 
The bacteria cause clinical syndromes such as typhoid fever and gastroenteritis in 
humans and animals after intake of contaminated water or food (Crump et al., 2004; 
Voetsch et al., 2004; Foley et al., 2006; Morpeth et al., 2009). The Salmonella genus 
is divided into two species: Salmonella enterica and Salmonella bongori (McQuiston 
et al., 2008, Lan et al., 2009). The Salmonella enterica (S. enterica) species is further 
classified into 6 subspecies: enterica, salamae, arizonae, diarizonae, hautenae and 
indica (Lan et al., 2009). Each subspecies has several serovars. Salmonella enterica 
subspecies enterica serovar Typhimurium (sometimes written simply as Salmonella 
enterica serovar Typhimurium) is a major nontyphoidal human pathogen worldwide 
(Gordon et al., 2008; Kingsley et al., 2009). In mice, this serovar causes typhoid-like 
symptoms and is therefore used as a mouse model for human typhoid fever caused 
by Salmonella enterica subspecies enterica serovar Typhi (Salmonella enterica 
serovar Typhi) (Santos et al., 2001). 
 
To develop vaccines against a number of Salmonella enterica species, mutations 
have been introduced into the genes that affect the metabolic pathways of the 
bacteria. The introduction of these specific mutations into genes such as aroC/D 
(aromatic amino acid synthesis), htrA (heat and oxidative stress), pur (purine 
biosynthesis), phoP/Q (phosphate metabolism) and dam (DNA adenine methylase 
expression) has been shown to attenuate the bacteria, thereby making them safe for 
use as vaccines (Castelli et al., 2000; Chamnongpol et al., 2003; Curtiss, 1993; 
Heithoff et al., 2001; Mutunga et al., 2004; Ritchie, 2006; Stocker, 2000). These 
attenuated Salmonella vaccines have also recently been used as delivery vectors for 
viral and other foreign antigens (Garmory et al., 2005; Galen et al., 2009; Kwon et 
al., 2007; Loessner et al., 2008). Viral antigens that were successfully expressed in 
attenuated recombinant Salmonella vaccines include the human papillomavirus 
(HPV)-16 L1 protein (Benyacoub et al., 1999), Hepatitis B virus nucleocapsid 
(Schodel et al., 1997), lymphocytic choriomeningitis virus (LCMV) nucleoprotein 
(Shams et al., 2001), feline immunodeficiency virus Gag (Tijhaar et al., 1997), 










Page | 32 
 
respiratory syncytial virus I (Shata et al., 2001), SIV p27 capsid (Steger et al., 1999),  
HIV-1 gp120 antigen (Fouts et al., 1995), and HIV-1 subtype C Gag (Chin‟ombe et 
al., 2009b). These studies showed that vaccination with Salmonella vaccines 
expressing the above mentioned proteins was associated with good humoral (IgA and 
IgG) and cell-mediated (CD8+ T) responses in animal models. 
 
To express a viral antigen in recombinant Salmonella, the coding DNA sequence of 
the gene is cloned into a prokaryotic expression plasmid vector. The expression 
plasmid contains the necessary transcription and translation domains such as the 
promoter, origin of replication, selection antibiotic resistance gene, Shine-Dalgarno 
(ribosome-binding site), transcription start and termination signals which are 
important for the expression of the foreign antigen (Hannig and Makrides, 1998; Jana 
and Deb, 2005). The recombinant expression plasmid is used in the transformation of 
the bacterium (Sambrook et al., 1989). In previous studies, it was shown that the 
coding sequences of green fluorescent protein (GFP) and human immunodeficiency 
virus type 1 subtype C Gag could be expressed at high levels in attenuated 
Salmonella enterica serovar Typhimurium (Chin‟ombe, 2007; Chin‟ombe et al., 
2009a,b; Seleem et al., 2008). In these studies, the genes of the foreign antigens were 
cloned into an expression plasmid and the expression was constitutively driven by 
the E. coli lactose (lac) promoter in pGEM -Teasy plasmid from Promega 
Corporation (USA). The genes were fused in-frame with the LacZα gene in the 
plasmid (Chin‟ombe, 2007; Chin‟ombe et al., 2009a,b). Mice vaccinated with the 
recombinant Salmonella bacteria elicited GFP and Gag-specific immune responses 
(Chin‟ombe, 2007; Chin‟ombe et al., 2009a,b). This showed that the recombinant 
bacterium successfully delivered the expressed foreign antigens to the immune 
system. It would, therefore, be interesting to use the same expression plasmid system 




The first objective of this study was to develop recombinant Salmonella enterica 
serovar Typhimurium expressing Tat, Nef and reverse transcriptase. This was 
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subtype C tat, nef and reverse transcriptase genes, individually, into the prokaryotic 
expression pGEM -Teasy plasmid. The genes were to be fused in-frame with the 
LacZa gene and expression driven by the E. coli lac promoter. An attenuated mutant 
strain of Salmonella enterica serovar Typhimurium was transformed with the 
recombinant expression plasmids (pGEM+Tat, pGEM+Nef and pGEM+RT) 
harbouring the HIV-1 tat, nef and rt genes. This was done for extraction of HIV-1 
subtype C Tat, Nef and RT proteins from Salmonella enterica serovar Typhimurium. 
The expression of the foreign antigens (Tat, Nef and RT) was evaluated by SDS-
PAGE and Western blotting. 
 
4.3 MATERIALS  
The source and properties of the bacterial strains, E. coli DH5α cells, aroC 
Salmonella enterica serovar Typhimurium mutant, and plasmids used in this study 
are given in Table 2.1. Restriction enzymes were supplied by Roche Diagnostics 
(Germany) and New England Biolabs (USA). Solutions and buffers are given in the 
Appendix A.  
 
Table 2.1: The source and properties of bacterial strains and plasmids used in 
the study. 
Material Nature of 
material 
Important properties Source 
DH5α E. coli 
bacterium 











plasmid Contains the gag-gfp 
(green fluorescence 
protein) gene fused to the 
lacZa and expression 
under the lac promoter 
Dr N. 
Chin‟ombe 
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4.4   METHODS 
A flow diagram of construction and evaluation of Salmonella enterica serovar 
Typhimurium expressing HIV-1 antigens (Tat, Nef and RT), is given in Figure 2.1).  
Briefly, HIV-1 genes (tat, nef and rt) were cloned from pScript+Tat, pScript+Nef 
and pScript+RT into a prokaryotic expression plasmid based on pGEM-Teasy vector 
and recombinant expression plasmids (designated pGEM+Tat, pGEM+Nef and 
pGEM+RT) were generated. The expression plasmids were used to transform the 
Salmonella enterica serovar Typhimurium. Evaluation of the expression of the HIV-
1 Tat, Nef and RT proteins by the bacteria was done by sodium dodecyl sulphate-












Figure 2.1 A flow Diagram of experimental strategy employed in chapter 2. 
 
4.4.1 Restriction mapping of HIV-1 genes (tat, nef and rt) in pScript+Tat, 
pScript+Nef and pScript+RT 
To check whether the provided plasmids (pScript+Tat, pScript+Nef and pScript+RT) 
contained the HIV-1 tat, nef and rt genes, restriction endonuclease mapping was 
used. The pScript+Tat, pScript+Nef and pScript+RT plasmids were digested using 
NarI (New England Biolabs, USA) and HpaI (Roche Diagnostics, Germany). The 
digestion contained: 500 ng of plasmid DNA, 1X restriction buffer (Roche 
Diagnostics, Germany), 5 U of enzyme and the reaction was done in a 20 µl volume.  
Transformation of Salmonella enterica serovar 
Typhimurium using recombinant plasmids 
 
Cloning of HIV-1 tat, nef and rt genes into prokaryotic expression 
plasmid (pGEM system)  
 
Evaluation of Tat, Nef and RT expression by 
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The digestions were incubated at 37 C for 1 hr. After the incubation, 2 µl of 6X 
loading dye was added and the digestions were analysed by 1.5% gel (Appendix A: 
11) electrophoresis.   
 
4.4.2 Preparation of HIV-1 tat, nef and rt genes from pScript+Tat, pScript+Nef 
and pScript+RT for cloning    
The tat, nef, and rt genes were excised out of the pScript+Tat, pScript+Nef and 
pScript+RT respectively using NarI and HpaI double digestion. Each digestion was 
prepared in a total volume of 50 µl with the following components: 1500 ng of 
plasmid DNA, 50 U of each enzyme and 1X of restriction buffer (Roche Diagnostics, 
Germany). Water was used to top-up the reaction volume to 50 µl. The digestions 
were incubated at 37 C for 2 hrs.  The digestions were then loaded onto 1.2% 
agarose gel (2 wells/reaction) and run until the gene fragments were separated from 
the pScript plasmid backbone.  
 
The tat, nef and rt bands were then excised from the agarose gel and purified using 
QIAGEN gel extraction kit according to manufacturer‟s instructions (QIAGEN , 
Germany). Briefly, the DNA fragments were excised from agarose gel, dissolved in 
Buffer QG (provided with the kit) and precipitated with isopropanol. The mixture 
was then transferred into a collection tube which was then put inside the provided 
QIAquick spin column and centrifuged at 10000 rpm (Eppendorf 5417C Centrifuge, 
Germany) for 1 min. The flow-through was discarded and 0.5 ml Buffer QG (reagent 
provided with the kit) was added to the collection tube and centrifuged again for 1 
min. The pellet bound to the QIAquick column was washed with 0.75 ml of Buffer 
PE and the DNA was eluted with 30 µl of water by centrifuging again at 10000 rpm 
(Eppendorf 5417C Centrifuge, Germany) for 1 min. 
 
The purified products were quantified by Nanodrop ND-1000 UV/VIS 
spectrophotometer (Thermo scientific, USA)  with absorbance of the DNA read at a 
wavelength of 260nm (A260) and 280nm (A280) to evaluate the purity of the 
preparation. The presence of purified products were further analysed by 1.2% 
agarose gel electrophoresis and the expected sizes of tat, nef and rt genes were 429 
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4.4.3 Preparation of plasmid expression (pGEM backbone) for cloning of tat, 
nef and rt genes  
The plasmid expression (pGEM) backbone was prepared from pGEM+SalmgagGFP 
plasmid, which contained the HIV-1 gag-green fluorescence protein (gfp) fusion 
gene between NarI and HindIII. Gag and gfp genes were in-frame with 5‟ domain of 
β-galactosidase α-gene (lacZa). The pGEM backbone was prepared by excising out 
the gag and gfp genes from the pGEM+SalmgagGFP plasmid. In order to remove the 
gfp fragment, the pGEM+SalmgagGFP was digested with HindIII in a total volume 
of 50 µl.  The digestion contained 1500 ng plasmid DNA and 50 U of the enzyme.  
After 1 hr incubation, at 37 C, 10 U of pfu polymerase was added to blunt the 
HindIII-digested ends and incubated for another hour at 72⁰C. The digestion product 
was purified using QIAGEN gel extraction kit according to manufacturer‟s 
instructions (QIAGEN, Germany). In order to excise the gag fragment from the 
HindIII-digested pGEM+Salmgag plasmid backbone, the following components 
were added into the digestion mix: 10 l of HindIII-digested pGEM+Salmgag 
product, 5 l of 10X restriction buffer, 5 l (50 U) of NarI enzyme and 30 µl of 
distilled water.  The mix was incubated at 37⁰C for 2 hrs and then loaded on 1.2% 
agarose gel. When the DNA fragments had separated, the pGEM backbone was 
excised from the agarose gel and purified using the QIAGEN gel extraction kit 
according to manufacturer‟s instructions as previously described on section 2.4.2 
(QIAGEN, Germany). The plasmid backbone was analyzed by 1.2% agarose gel 
electrophoresis DNA concentration determined by the Nanodrop ND-1000 UV/VIS 
spectrophotometer (Thermo scientific, USA).   
 
4.4.4 Determination of DNA concentration by Nanodrop  
The DNA of purified pGEM backbone, tat, nef and rt genes was quantified using a 
Nanodrop ND-1000 UV/VIS spectrophotometer (Thermo scientific, USA). The 
absorbance of the DNA was read at a wavelength of 260nm (A260) and 280nm (A280). 
The ratio between these wavelengths provides an approximate purity of the sample 
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2.4.5 Ligation of HIV-1 genes (tat, nef and rt) into pGEM backbone 
The HIV-1 tat, nef and rt gene fragments, which were previously prepared (Section 
2.4.2) were individually ligated into the previously-prepared pGEM plasmid 
backbone (Section 2.4.3) as shown on Figures 2.2-2.4. Each ligation reaction 
contained vector DNA (80 ng) and insert DNA (40 ng), 1X ligation buffer (Roche, 
Germany), 20 U of T4 DNA ligase (Roche Diagnostics, Germany) and the reaction 
was done in a total volume of 10 µl. Ligation digestions were prepared on ice and 
incubated for overnight at 4 C. Two ligation controls were included, (1) a negative 
ligation control including a ligation digestion with only vector but no insert. This was 
used to identify if there were any false results due to the re-ligation of the vector, (2) 
pScript+Tat plasmid DNA was used as positive control to identify the positive 
results. The products of the ligation digestion were ready for transformation into E. 
coli DH5α cells. 
 
2.4.6 Transformation of competent E. coli DH5α cells with plasmid 
Competent E. coli DH5α bacterial cells were prepared using the calcium chloride 
method (Sambrook et al., 1989). Briefly, 100 µl of culture from E. coli stock were 
streaked onto 2x yeast tryptone (YT) agar plates (Appendix A: 1) and grown at 37
o
C 
overnight. A single colony was selected from the plate and inoculated in a total 
volume of 15 ml of 2xYT media (Appendix A: 2) and grown at 37
o
C overnight 
shaking. A 5 ml of the culture was diluted into 200 ml of 2xYT media (Appendix A: 
2) and grown until the cells reached logarithmic phase (Absorbance values between 
0.5 and 0.6 at 600 nm). The bacterial cultures (100 ml) were harvested at 5000 rpm 
(Sorvall RC-5C Plus superspeed centrifuge, Rotor S/N 10300651, USA) for 5 min at 
4
o
C and suspended in 0.1 M ice-cold calcium chloride (Appendix A: 8). The cells 
were incubated on ice for 60 min. The cells were reharvested by centrifugation and 
resuspended in 8 ml of ice-cold 0.1 M calcium chloride containing 10% glycerol 
solution (Appendix A: 7). The cells were stored at -80⁰C in 100 µl aliquots.  
The ligation reactions (section 2.2.4) were used to transform the competent bacterial 
cells using the heat-shock method (Sambrook et al., 1989). Briefly, frozen 100 µl 
aliquots of competent E. coli DH5α cells were thawed on ice and 10 µl of each 
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ice for 30 min. The cells were heat-shocked at 42 C in a water bath for 2 min and 
incubated on ice for 2 min. Nine-hundred microliters (µl) of 2xYT broth was added 
and the cells were incubated at 37
o
C for 1 hr. The cells were then plated onto 2xYT 
agar supplemented with 100 µg/ml ampicillin (Appendix A: 3) and incubated at 37 C 
overnight. The following morning, the bacterial colonies from each transformation 






















Figure 2.2 Construction of pGEM+Tat by DNAMAN software version 4.0 (Lynnon 
Biosoft, Canada). The tat gene was digested from pScript+Tat using NarI (sticky cutter) and 
HpaI (blunt cutter). The gene was cloned into the pGEM backbone prepared from digesting 
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Figure 2.3: Construction of pGEM+Nef by DNAMAN software version 4.0 (Lynnon 
Biosoft, Canada). The nef gene was digested from pScript+Nef using NarI (sticky cutter) 
and HpaI (blunt cutter). The gene was cloned into the pGEM previously prepared from 
pGEM+SalmgagGFP. 
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Figure 2.4: Construction of pGEM+RT by DNAMAN software version 4.0 (Lynnon 
Biosoft, Canada). The rt gene was digested from pScript+RT using NarI (sticky cutter) and 
HpaI (blunt cutter). The gene was cloned into the pGEM previously prepared from 
pGEM+SalmgagGFP. 
 
2.4.7 Screening of recombinant E. coli DH5α colonies for correct plasmid  
Bacterial colonies (5 per plate) from each transformation were inoculated into 15 ml 
2xYT media supplemented with 100 µg/ml ampicillin (Appendix A: 3) and 
incubated at 37⁰C overnight. The following morning, plasmid DNA was isolated 
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bacterial culture was harvested by centrifugation at 5000 rpm (Eppendorf 5417C 
Centrifuge, Germany) for 5 min and the pellet was resuspended in 400 µl of 
resuspension buffer (Appendix A: 12). Freshly prepared lysis buffer (400 µl) 
(Appendix A: 13) was added to the cells and the suspension was incubated at room 
temperature for 5 min. A neutralization buffer (400 µl) (Appendix A: 14) was added 
and the suspension was inverted 4-6 times before incubation on ice for 5 min. After 
pelleting cell debris at 14000 rpm (Eppendorf 5417C Centrifuge, Germany) for 10 
min, 900 µl of the supernatant was added to 644 µl of isopropanol in a new 
eppendorf tube and centrifuged at 14000 rpm (Eppendorf 5417C Centrifuge, 
Germany) for 15 min. The pelleted plasmid DNA was washed with 700 µl of 70% 
ethanol (Appendix A: 15) by centrifuging at 14000 rpm (Eppendorf 5417C 
Centrifuge, Germany) for 10 min. The plasmid DNA pellet from each preparation 
was dried and suspended in 30 µl of distilled water. The quantities of the DNA 
preparations were done using the Nanodrop ND-1000 UV/VIS spectrophotometer 
(Thermo scientific, USA) as described previously (section 2.4.4). 
 
The recombinant plasmids (designated pGEM+Tat, pGEM+Nef and pGEM+RT) 
were screened by restriction enzyme mapping using EcoRI (Roche Diagnostics, 
Germany) that cut at the N-terminus and C-terminus of each gene (tat, nef and rt, 
respectively). The restriction digestion of each plasmid contained 500 ng of plasmid 
DNA, 1X of restriction buffer and 10 U of restriction enzyme. The digestion was 
made in a total volume of 20 µl at 37 C for 2 hrs. The digested DNA was analysed 
using 1.5% agarose gel electrophoresis. To confirm the presence of the tat, nef and rt 
genes in selected pGEM+Tat, pGEM+Nef and pGEM+RT, respectively, the 
plasmids were sent to Central DNA Sequencing Facility for sequencing (Department 
of Genetics, University of Stellenbosch). The sample reactions included 100 ng of 
plasmid DNA (pGEM+Tat, pGEM+Nef and pGEM+RT), 1 pmol/µl of M13 forward 
sequencing primer {5‟-(CGCCAGGGTTTTCCCAGTCACGAC)-3‟} and 1 pmol/µl 
M13 reverse sequencing primer {5´-(TCACACAGGAAACAGCTATGAC)-3´}. The 
product sizes of pGEM+Tat, pGEM+Nef and pGEM+RT plasmid were 3426 bp, 
3652 bp and 4378 bp, respectively. The DNA sequences for each plasmid were 
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2.4.8 Transformation of Salmonella enterica serovar Typhimurium  
The growth conditions for Salmonella enterica serovar Typhimurium and E. coli 
were the same except that 100 µg/ml aromix compounds (Appendix A: 5) and 100 
µg/ml tyrosine (Appendix A: 6) were added into media for Salmonella. Competent 
Salmonella enterica serovar Typhimurium cells were prepared using calcium 
chloride as previously described for E. coli (section 2.4.6). The cells were 
transformed with the pGEM+Tat, pGEM+Nef and pGEM+RT plasmids using the 
heat-shock method as previously described. The plates were incubated overnight at 
37°C.  
2.4.9 Extraction of total bacterial protein from Salmonella enterica serovar 
Typhimurium 
A single bacterial colony from recombinant Salmonella enterica serovar 
Typhimurium harbouring the pGEM+Tat, pGEM+Nef or pGEM+RT was inoculated 
into 100 ml 2xYT media with 100 µg/ml of ampicillin, aromix and tyrosine 
(Appendix A: 3, 5 and 6) and grown at 37⁰C overnight on a shaker. Extraction of the 
total protein from recombinant Salmonella enterica serovar Typhimurium was 
performed using the SDS-lysis method. The bacterial culture (4 ml) was pelleted at 
6000 rpm (Eppendorf 5417C Centrifuge, Germany) for 5 min at 4
o
C. The pellet was 
washed with 1ml of cold PBS (pH 7.4) at 14000 rpm (Eppendorf 5417C Centrifuge, 
Germany) for 10 min at 4
o
C and resuspended in 500 µl of protein lysis buffer 
(Appendix A: 26). The suspension was boiled in a water bath for 30 min and the 
supernatant containing the total protein was clarified by centrifuging at 14000 rpm 
(Eppendorf 5417C Centrifuge, Germany) for 10 min at 4
o
C. The supernatant was 
transferred into a new Eppendorf tube and the protein concentrations were 
quantified. 
 
2.4.10 Determination of protein concentration by Bio-Rad DC assay 
The concentration of the extracted recombinant Salmonella protein was determined 
using the Bio-Rad DC protein assay kit according to manufacturer‟s instructions. The 
bovine serum albumin (BSA) was used to prepare a standard curve. Several dilutions 
(0.1, 0.2, 0.4, 0.8, 1.2, 1.6 and 2.0 µg/µl) of BSA were made with 1X CAT lysis 
buffer and the absorbance was measured at 750nm using a VERSmax microplate 
reader (Bio-rad, Canada). Using the absorbance measured, the BSA standard curve 
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2.4.11 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
In order to confirm the protein expression by recombinant bacteria, sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was used. A 12.5% 
resolving gel was prepared (Appendix A: 22) and poured into the plates leaving 
approximately 4 cm on top of the resolving gel for the stacking gel. The resolving gel 
was overlaid with water-saturated butanol and allowed to solidify at room 
temperature for about an hour. After the gel was polymerised, the butanol was 
removed. A 4% stacking gel was prepared (Appendix A: 23) and poured into the 
space left in the plates on top of the resolving gel. The sample comb was inserted 
into 4% stacking gel to generate sample wells and allowed it to polymerise at room 
temperature for an about 30 min. Once the gel was polymerized, 20 µl of 500 ng 
protein was mixed with 2X Laemmli loading buffer (Appendix A: 21) at a ratio of 
1:4 and boiled for 5 min to denature the proteins. The protein samples (20 µl per 
well) were loaded and run for 15 min at 60 V and a further 2 hrs at 80 V. A spectrum 
broad range colour stained marker (Inqaba biotec, Canada) was loaded to identify the 
sizes of the proteins as well as to monitor the protein separation in the gel during 
electrophoresis. Two duplicate SDS-PAGE gels were always prepared: one gel for 
Coomassie blue staining (Appendix A: 34) and the other gel for Western blotting.   
 
2.4.12 Coomassie blue staining and destaining 
Coomassie Brilliant blue solution (Appendix A: 34) was used to stain the SDS-
PAGE gels. The gels were covered with Coomassie blue staining solution and 
incubated on a slight shaking for about 2 hrs. To destain the protein gels, the staining 
was removed and washed with destaining solution (Appendix A: 35) 5 times on a 
shaker (Orbital Shaker SO3, USA) and left on destaining solution overnight at room 
temperature. The destained gel was then placed on a light box and photographed with 
a Sony DSC-P73 digital camera. 
2.4.13 Western blotting of total bacterial proteins to detect recombinant 
proteins 
Total bacterial proteins (only from Salmonella expressing Nef or RT) were 
transferred from the SDS-PAGE gel to the Hybond-P polyvinylidene difluoride 
(PVDF) membrane (Amersham, UK) by Western blotting.  The SDS-PAGE gel was 
equilibrated in 1X transfer buffer (Appendix A: 33) for 20 min. While waiting for 
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the dimensions of the gel and pre-wetted in 100% methanol for 5 min, rinsed with 
distilled water for 10 min and equilibrated in the transfer buffer for 20 min. The filter 
papers were also cut to the dimensions of the gel and saturated by soaking in the 
transfer buffer for 20 min. The saturated filter paper was placed bottom, followed by 
membrane and a gel on top of the membrane. The other pre-soaked filter paper was 
placed on top of the gel. Each layer of the sandwich was rolled over with a glass 
pipette to remove the air bubbles. Electroblotting was carried out by applying a 
constant voltage of 15 V for 60 min at room temperature. The membrane was 
incubated in blocking buffer (Appendix A: 30) at 4
o
C overnight prior to 
immunodetection.  
 
2.4.14 Immunodetection of recombinant Nef and RT on Western blots  
To detect Nef or RT from the Western blots, mouse anti-Nef (Sigma, Germany) and 
rabbit anti-RT (Sigma, Germany) antibodies respectively, diluted 1:500, were added 
after removal of blocking buffer. The blots were incubated for 2 hrs at room 
temperature and then washed four times with an excess amount of washing buffer 
(Appendix A: 30) for 10 min each. A secondary goat anti-mouse IgG antibody 
conjugated to alkaline phosphatase (Sigma, Germany) and a sheep anti-rabbit IgG 
antibody conjugated horseradish peroxidase (Sigma, Germany) (diluted 1.1000) were 
added to the respective blots. The blots were incubated for 1 hr at room temperature. 
The blots were washed four times with washing buffer (Appendix A: 30) for 10 min 
each. The Nef was detected from the blot using NBT-BCIP (Nitro Blue Tetrazolium 
chloride-5-Bromo-4-Chloro-3-Indolyl Phosphate) substrate (Roche Diagnostics, 
Germany) following the manufacturer‟s instructions. The RT protein was detected 
from the blot using the Nova Red Substrate solution (Vector Laboratories, CA, 
USA). The blots were covered with the substrate solutions until Nef or RT protein 
bands had developed. The blots were rinsed in water, air-dried and scanned 
















Page | 45 
 
2.5.1 Verification of the plasmids with restriction mapping 
The pScript+Tat, pScript+Nef and pScript+RT plasmids containing the HIV-1 tat, 
nef and rt genes, respectively, were mapped using NarI and HpaI restriction 
enzymes. The generated DNA fragments were analysed by agarose gel 
electrophoresis and they were all observed with expected molecular weights (Figure 
2.5 A-C, lanes 2). The sizes of the produced fragments are given in Table 2.1. The 
expected DNA sizes of tat, nef and rt fragments after restriction digestions were 400 
bp, 626 bp and 1352 bp respectively (Table 2.1). The pScript+RT generated three 
bands (Figure 2.5C, lane 2), where the 510 bp was p51 (rt) cloned between two HpaI 
sites and the 1352 bp was the other rt gene (p66) cloned between NarI and HpaI. The 
pScript backbone band was 2945 bp. 
 
 
Figure 2.5:  Restriction mapping of pScript+Tat, pScript+Nef and pScript+RT 
plasmids using NarI and HpaI. (A) Restriction mapping of pScript+Tat. Lane 1: 
O‟Generuler 100 bp DNA ladder, Lane 2: pScript+Tat digested with NarI and HpaI, (B) 
Restriction mapping of pScript+Nef. Lane 1: O‟Generuler 100 bp DNA ladder, Lane 2: 
pScript+Nef digested with NarI and HpaI. (C) Restriction mapping of pScript+RT. Lane 
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Table 2.1: Predicted sizes of DNA after restriction mapping of pScript+Tat, 
pScript+Nef and pScript+RT  
 
Plasmid Name Restriction Enzymes Expected DNA band sizes (bp) 
pScript+Tat NarI and HpaI 400  and 2945 
pScript+Nef NarI and HpaI 626 and 2945 




2.5.2 HIV-1 tat, nef and rt cloning into pGEM expression plasmid backbone 
The pGEM+SalmgagGFP had gag and green fluorescence protein (gfp) genes cloned 
in-frame with 5‟ domain of β-galactosidase α-gene (lacZa). In order to remove gag 
and gfp, pGEM+SalmgagGFP was initially digested with HindIII to release the gfp 
gene (Figure 2.6A). Two DNA bands were expected on the agarose gel (Figure 2.6A; 
Table 2.2). The smaller DNA fragment was the gfp gene and the bigger fragment was 
the linearized plasmid which still contained the HIV-1 gag gene. The ends of the 
plasmid were then blunt-ended using pfu polymerase and the plasmid was further 
digested with NarI to excise out the HIV-1 gag gene (Figure 2.6B). The released 
HIV-1 gag gene was 1470 bp and the pGEM plasmid backbone was 3026 bp (Figure 
26B, Table 2.2). Ther  was incomplete digestion of the plasmid with NarI and there 
were other bands above the 3026 bp band (Figure 2.6B, lane 2). A 3026 bp band for 
the pGEM plasmid backbone was cut and gel-purified (Figure 2.6C, lane 2).  
 
The HIV-1 tat, nef and rt genes were excised from the pScript+Tat, pScript+Nef and 
pScript+RT plasmids respectively using NarI and HpaI and purified (Figure 2.7). The 
expected sizes of the genes were observed on agarose gels (Figure 2.7; A, lane 2; B, 
lane 2 & C, lane 2). In order to construct the pGEM+Tat, pGEM+Nef and 
pGEM+RT plasmids, the tat, nef and rt genes were individually ligated into the 
pGEM backbone and competent E. coli cells transformed. Most colonies screened 
had plasmid DNA which contained the respective HIV-1 (tat, nef and rt) genes (data 
not shown). The restriction mapping of the candidate plasmids DNA containing 
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(Figure 2.8; A, lane 2; B, lane 2 & C, lanes 2). The frame of the HIV-1 tat, nef and rt 
genes in pGEM+Tat, pGEM+Nef and pGEM+RT was further confirmed by 
sequencing the plasmids (section 2.5.3).  
 
Table 2.2: Predicted sizes of DNA after restriction digestion of 
pGEM+SalmgagGFP to prepare pGEM backbone 
Plasmid Restriction Enzymes Expected DNA band 
sizes (bp) 
pGEM+SalmgagGFP HindIII 747  and 4496 




Figure 2.6: Preparation of pGEM backbone. (A) The pGEM+SalmgagGFP plasmid was 
digested with HindIII and blunt-ended with Pfu polymerase. Lane 1: DNA/PstI DNA 
ladder, Lane 2: Linearized pGEM+Salmgag (upper band) and gfp (lower band) after 
digestion with HindIII (B) Linearized pGEM+Salmgag after digestion with NarI to release 
gag fragment. Lane 1: DNA/PstI DNA ladder, Lane 2: pGEM backbone (upper band), gag 
(middle band) and gfp (lower band) (C) Gel-purified pGEM backbone. Lane 1: Marker VI, 
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Figure 2.7: Purified HIV-1 tat, nef and rt genes. (A) A tat fragment was excised (Figure 
2.6 A) and gel-purified. Lane 1: O‟Generuler 100 bp DNA ladder, Lane 2: tat gene (B) A 
nef fragment was excised (Figure 2.6 B) and gel-purified. Lane 1: O‟Generuler 100 bp DNA 
ladder, Lane 2: nef gene. (C) A rt fragment was excised (Figure 2.6 C) and gel-purified. 
Lane 1: O‟Generuler 1kb DNA ladder, Lane 2: rt gene. 
 
 
Table 2.3: Predicted sizes of DNA after restriction mapping of candidate 
pGEM+Tat, pGEM+Nef and pGEM+RT plasmids  
 
Plasmid Restriction Enzyme Expected DNA band sizes (bp) 
pGEM+Tat EcoRI 429  and 2997 
pGEM+Nef EcoRI 655  and 2997 


















Figure 2.8: Restriction analysis of pGEM+Tat, pGEM+Nef and pGEM+RT. (A) A 
pGEM+Tat plasmid digested with EcoRI. Lane 1: O‟Generuler 100 bp DNA ladder, Lane 2: 
pGEM+Tat. (B) A pGEM+Nef plasmid digested with EcoRI. Lane 1: O‟Generuler 1kb 
DNA ladder, Lane 2: pGEM+Nef. (C) A pGEM+RT plasmid digested with EcoRI. Lane 1: 
O‟Generuler 1 kb DNA ladder, Lane 2: pGEM+RT digested with EcoRI.  
 
 
2.5.3 Sequencing of pGEM+Tat, pGEM+Nef and pGEM+RT  expression 
plasmids 
The candidate plasmids, pGEM+Tat, pGEM+Nef and pGEM+RT, were sequenced to 
confirm the restriction mapping results. The sequences were confirmed to be correct 
according to the rt, tat and nef gene sequences (Burgers et al., 2006) using 
DNAMAN version 4.0 sequence analysis software (Lynnon Biosoft, Canada) 
{Figure 2.10A (tat gene from 30 bp to 504 bp), Figure 2.10B (nef gene from 30 bp to 
729 bp) and Figure 2.10C (rt gene from 32 bp to `1467 bp)}. Based on the DNA 
sequence data, the maps of the three plasmids (pGEM+Tat, pGEM+Nef and 
pGEM+RT) were drawn (Figure 2.9, A - C). The DNA coding and protein sequences 
of the expressed proteins (Tat, Nef and RT) were also concluded from the sequence 
data (Figure 2.10, A - C). The pGEM+Tat, pGEM+Nef and pGEM+RT plasmids 
DNA had the tat, nef and rt genes, respectively, fused in-frame with E. coli β-
galactosidase α-fragment (lacZα) sequence under the expression of the upstream E. 
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-galactosidase-Nef and -galactosidase-RT fusion proteins were 19 kDa, 30 kDa 
and 59 kDa, respectively. The genes used the ATG start codon of -galactosidase 
and they all had TAA as a stop codon. 
 
Figure 2.9: Maps of pGEM+Tat, pGEM+Nef and pGEM+RT expression plasmids, 
constructed using DNAMAN software version 4.0 (Lynnon Biosoft, Canada). These 
plasmids had HIV-1 subtype C tat, nef and rt genes which were previously cloned into the 
pGEM backbone fused in frame with the β-galactosidase α-gene (lacZa). The expression of 
the fusion protein was the under upstream E. coli lac promoter.  
 
1         ATGACCATGATTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
1          M  T  M  I  T  P  S  Y  L  G  D  T  I  E  Y  S  S  Y  A  S  
 
61        AACGCGTTGGGAGCTCTCCCATATGGTCGACCTGCAGGCGGCCGCGAATTCACTAGTGAT 
21         N  A  L  G  A  L  P  Y  G  R  P  A  G  G  R  E  F  T  S  D   
 
121       TATGGCGCCCATATGCTGGGCATTAGCTATGGCCGCAAAAAACGTCGTCAGCGTCGTAGC 
41         Y  G  A  H  M  L  G  I  S  Y  G  R  K  K  R  R  Q  R  R  S   
 
181       ACCCCGCCGAGCAGCGAAGATCATCAGAACCCGATTAGCAAACAGCCGCTGCCGCAGACC 
61         T  P  P  S  S  E  D  H  Q  N  P  I  S  K  Q  P  L  P  Q  T   
 
241       CGTGGCGATCCGACCGGCAGCGAAGAAAGCAAAAAAAAAGTCGAAAGCAAAACCAAAACC 
81         R  G  D  P  T  G  S  E  E  S  K  K  K  V  E  S  K  T  K  T   
 
301       GATCCGTTTGATTGCAAATATTGCAGCTATCACTGCCTGGTGTGCTTTCAGACCAAAGGT 
101        D  P  F  D  C  K  Y  C  S  Y  H  C  L  V  C  F  Q  T  K  G   
 
361       CTGGGTATCTCCTACGGTCGTAAAAAGCGCATGGAACCGATTGATCCGAATCTGGAACCG 
121        L  G  I  S  Y  G  R  K  K  R  M  E  P  I  D  P  N  L  E  P   
 
421       TGGAATCATCCGGGCAGCCAGCCGAATACCCCGTGCAACAAATGCTATTGTAAGTACTGT 
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481       TCCTACCATTGCTTGGTCGACTAA 
161        S  Y  H  C  L  V  D  * 
 
1         ATGACCATGATTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
1          M  T  M  I  T  P  S  Y  L  G  D  T  I  E  Y  S  S  Y  A  S  
 
61        AACGCGTTGGGAGCTCTCCCATATGGTCGACCTGCAGGCGGCCGCGAATTCACTAGTGAT 
21         N  A  L  G  A  L  P  Y  G  R  P  A  G  G  R  E  F  T  S  D   
 
121       TATGGCGCCCATATGGTGGGCTGGCCGGCGGTGCGTGAACGTATTCGTCGTACCGAACCG 
41         Y  G  A  H  M  V  G  W  P  A  V  R  E  R  I  R  R  T  E  P   
 
181       GCGGCGGAAGGCGTGGGCGCGGCGAGCCAGGATCTGGATAAACATGGCGCGCTGACCAGC 
61         A  A  E  G  V  G  A  A  S  Q  D  L  D  K  H  G  A  L  T  S   
 
241       AGCAATACCGCGCATAACAATCCGGATTGCGCGTGGCTGCAAGCGCAGGAAGAAGAACCG 
81         S  N  T  A  H  N  N  P  D  C  A  W  L  Q  A  Q  E  E  E  P   
 
301       GAAGTCGGCTTTCCGGTCCGTCCGCAGGTGCCGCTGCGTCCGATGACCTATAAAGCGGCG 
101        E  V  G  F  P  V  R  P  Q  V  P  L  R  P  M  T  Y  K  A  A   
 
361       TTTGATCTGAGCTTTTTTCTGAAAGAAAAAGGCGGCCTGGAGGGCCTGATCTATAGCAAA 
121        F  D  L  S  F  F  L  K  E  K  G  G  L  E  G  L  I  Y  S  K   
 
421       AAACGCCAGGATATTCTGGATTTATGGGTCTATCATACCCAGGGCTATTTTCCGGATTGG 
141        K  R  Q  D  I  L  D  L  W  V  Y  H  T  Q  G  Y  F  P  D  W   
 
481       CAGAATTATACCCCGGGTCCGGGCGTGCGTCTGCCGCTGACCTTTGGCTGGTGCTTTAAA 
161        Q  N  Y  T  P  G  P  G  V  R  L  P  L  T  F  G  W  C  F  K   
 
541       CTGGTGCCGGTCGATCCGGAAGAAGTGGAAGAAGCGAACAAAGGCGAAAACAACTGTCTG 
181        L  V  P  V  D  P  E  E  V  E  E  A  N  K  G  E  N  N  C  L   
 
601       CTGCATCCGCTGAGCCAGCATGGCATGGAAGATGCGGATCGCGAAGTCCTGAAATGGGTC 
201        L  H  P  L  S  Q  H  G  M  E  D  A  D  R  E  V  L  K  W  V   
 
661       TTTGATAGCAGCCTGGCGCGTCGTCATCTGGCGCGTGAAAAACATCCGGAATATTATAAA 
221        F  D  S  S  L  A  R  R  H  L  A  R  E  K  H  P  E  Y  Y  K   
 
721       GATGCATAA 
241        D  A  *     
 
 
1         ATGACCATGATTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
1          M  T  M  I  T  P  S  Y  L  G  D  T  I  E  Y  S  S  Y  A  S  
 
61        AACGCGTTGGGAGCTCTCCCATATGGTCGACCTGCAGGCGGCCGCGAATTCACTAGTGAT 
21         N  A  L  G  A  L  P  Y  G  R  P  A  G  G  R  E  F  T  S  D   
 
121       TATGGCGCCCATATGGGGCCCATTAGCCCGATTGAAACCGTGCCGGTGAAACTGAAACCG 
41         Y  G  A  H  M  G  P  I  S  P  I  E  T  V  P  V  K  L  K  P   
 
181       GGCATGGATGGCCCGAAAGTCAAACAGTGGCCGCTGACCGAAGTGAAAATTAAAGCGCTG 
61         G  M  D  G  P  K  V  K  Q  W  P  L  T  E  V  K  I  K  A  L   
 
241       ACCGCGATTTGCGAAGAAATGGAAAAAGAAGGCAAAATCACCAAAATCGGCCCGGAAAAC 
81         T  A  I  C  E  E  M  E  K  E  G  K  I  T  K  I  G  P  E  N   
 
301       CCGTATAACACCCCGATCTTTGCGATCAAAAAAGAAGATAGCACCAAATGGCGTAAACTG 
101        P  Y  N  T  P  I  F  A  I  K  K  E  D  S  T  K  W  R  K  L   
 
361       GTGGATTTTCGCGAACTGAACAAACGCACCCAGGATTTTTGGGAAGTCCAACTGGGCATT 
121        V  D  F  R  E  L  N  K  R  T  Q  D  F  W  E  V  Q  L  G  I   
 
421       CCGCATCCGGCGGGCCTGAAGAAAAAGAAAAGCGTGACCGTGCTGGATGTCGGCGATGCG 
141        P  H  P  A  G  L  K  K  K  K  S  V  T  V  L  D  V  G  D  A   
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161        Y  F  S  V  P  L  D  E  G  F  R  K  Y  T  A  F  T  I  P  S   
 
541       ATCAACAATGAAACCCCGGGCATTCGCTATCAGTATAACGTGCTGCCGCAGGGCTGGAAA 
181        I  N  N  E  T  P  G  I  R  Y  Q  Y  N  V  L  P  Q  G  W  K   
 
601       GGCAGCCCGGCGATTTTTCAGGCGAGCATGACCAAAATTCTGGAACCGTTTCGCGCGAAA 
201        G  S  P  A  I  F  Q  A  S  M  T  K  I  L  E  P  F  R  A  K   
 
661       AACCCGGAAATCGTGATCTATCAGTATATGGCGGCGCTGTATGTGGGCAGCGATCTGGAA 
221        N  P  E  I  V  I  Y  Q  Y  M  A  A  L  Y  V  G  S  D  L  E   
 
721       ATTGGCCAGCATCGCGCGAAAATTGAAGAACTGCGCGAACATCTGCTGAAATGGGGCTTT 
241        I  G  Q  H  R  A  K  I  E  E  L  R  E  H  L  L  K  W  G  F   
 
781       ACCACCCCGGATAAAAAACACCAGAAAGAACCGCCGTTTTTATGGATGGGCTATGAACTG 
261        T  T  P  D  K  K  H  Q  K  E  P  P  F  L  W  M  G  Y  E  L   
 
841       CATCCGGATAAATGGACCGTCCAGCCGATTCAACTGCCGGAAAAAGATAGCTGGACCGTC 
281        H  P  D  K  W  T  V  Q  P  I  Q  L  P  E  K  D  S  W  T  V   
 
901       AACGATATTCAGAAACTGGTGGGCAAACTGAATTGGACCAGCCAGATTTATCCGGGCATT 
301        N  D  I  Q  K  L  V  G  K  L  N  W  T  S  Q  I  Y  P  G  I   
 
961       AAAGTGCGTCAGTTATGCAAACTGCTGCGTGGCACCAAAGCGCTGACGGATATTGTCCCG 
321        K  V  R  Q  L  C  K  L  L  R  G  T  K  A  L  T  D  I  V  P   
 
1021      CTGACGGAAGAAGCGGAACTGGAACTGGCGGAAAACCGCGAAATTCTGAAAGAACCTGTG 
341        L  T  E  E  A  E  L  E  L  A  E  N  R  E  I  L  K  E  P  V   
 
1081      CACGGCGTCTATTATGATCCGAGCAAAGATCTGATTGCGGAAATCCAGAAACAGGGCGAT 
361        H  G  V  Y  Y  D  P  S  K  D  L  I  A  E  I  Q  K  Q  G  D   
 
1141      GACCAGTGGACCTATCAGATCTATCAGGAACCGTTTAAAAACCTGAAAACCGGCAAATAT 
381        D  Q  W  T  Y  Q  I  Y  Q  E  P  F  K  N  L  K  T  G  K  Y   
 
1201      GCGAAACGTCGCACCACCCATACCAACGATGTGAAACAACTGACCGAAGCGGTGCAGAAA 
401        A  K  R  R  T  T  H  T  N  D  V  K  Q  L  T  E  A  V  Q  K   
 
1261      ATCAGCCTGGAAAGCATTGTGACCTGGGGCAAAACCCCGAAATTTCGCCTGCCGATCCAG 
421        I  S  L  E  S  I  V  T  W  G  K  T  P  K  F  R  L  P  I  Q   
 
1321      AAAGAAACCTGGGAAATCTGGTGGACCGATTATTGGCAGGCGACCTGGATTCCGGAATGG 
441        K  E  T  W  E  I  W  W  T  D  Y  W  Q  A  T  W  I  P  E  W   
 
1381      GAATTTGTTAATACCCCGCCGCTGGTGAAACTGTGGTATCAACTGGAAAAAGAACCGATT 
461        E  F  V  N  T  P  P  L  V  K  L  W  Y  Q  L  E  K  E  P  I   
 
1441      GCGGGCGCGGAAACGTTCCATGCATAA 
481        A  G  A  E  T  F  H  A  *     
Figure 2.10: The DNA coding and protein sequences of Tat (A), Nef (B) and RT (C) 
proteins fused to LacZα, constructed using DNAMAN software version 4.0 (Lynnon 
Biosoft, Canada). The LacZα sequences are given in pink and the Tat, Nef and RT 
sequences are given in green. ATG and TAA sequences are given in black and were used as 
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2.5.4 Expression of HIV-1 Tat, Nef and RT by Salmonella enterica serovar 
Typhimurium 
The expression of HIV-1 Tat, Nef and RT proteins by the recombinant Salmonella 
enterica serovar Typhimurium was evaluated by SDS-PAGE. The expected band 
sizes of the β-galactosidase-Tat, β-galactosidase-Nef and β-galactosidase-RT on the 
SDS-PAGE gels were 19 kDa, 30 kDa and 59 kDa, respectively. The protein bands 
for Tat, Nef and RT were visible on the Coomassie-stained SDS-PAGE gels (Figures 
2.11, lane 2; Figures 2.12A, lane 2; Figures 2.13A, lane 2). The foreign proteins 
seemed to be most highly expressed bacterial proteins. Western blotting was further 
used to confirm the expression of Tat, Nef and RT proteins (Figures 2.12B; Figures 
2.13B). The anti-Nef antibody reacted strongly with the Nef protein band (Figures 
2.12B, lane 2). The anti-RT antibody also reacted with the RT band (Figures 2.13B, 
lane 2). However, the Western blot also showed that there were other smaller protein 
bands that reacted with RT antibody (Figure 2.13B, lane 2). No reactivity of the anti-
Nef or anti-RT antibodies to the recombinant Salmonella carrying the empty plasmid 
(pUC19) was observed (Figures 2.12B, lane 3; Figures 2.13B, lane 3).  
 
 
Figure 2.11: The SDS-PAGE gel showing the expression of the Tat protein by 
recombinant Salmonella enterica serovar Typhimurium. Lane 1: Marker, Lane 2: 
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Figure 2.12: The expression of the Nef protein by recombinant Salmonella enterica 
serovar Typhimurium. A is a Coomassie-stained SDS-PAGE gel and B is a Western blot 
with Nef protein detected with anti-Nef antibody. Lane 1: Marker, Lane 2: Salmonella 








Figure 2.13: The expression of the RT protein by recombinant Salmonella enterica 
serovar Typhimurium. A is a Coomassie-stained SDS-PAGE gel and B is a Western blot 
with RT protein detected with anti-RT antibody. Lane 1: Marker, Lane 2: Salmonella 






















HIV-1 Tat, Nef and RT are important viral antigens which have previously been 
expressed in E. coli (Lader et al., 1987; Kaminchik et al., 1990; Orsini et al., 1996; 
Lebeko, 2007). In this study, HIV-1C tat, nef and rt genes derived from Southern 
Africa and targeted for AIDS vaccine development (Burgers et al., 2006; Williamson 
et al., 2003) were cloned and expressed in recombinant Salmonella enterica serovar 
Typhimurium mutant.  
 
2.6.1 Cloning of HIV-1 subtype C tat, nef and rt genes 
The tat, nef and rt genes were codon-optimized (by Geneart, Germany) for 
expression in Salmonella enterica serovar Typhimurium and were received in 
plasmids, pScript+Tat, pScript+Nef and pScript+RT respectively. The genes ( tat, nef 
and rt) in these plasmids were cloned between the two restriction enzymes NarI and 
HpaI which generate sticky and blunt ends respectively. The initial objective of this 
study was to clone HIV-1 subtype C tat, nef and rt genes into a Salmonella 
prokaryotic expression system previously developed by Chin‟ombe and colleagues 
(Chin‟ombe et al., 2009a). The expression system is based on the use of the 
Escherichia coli lactose (lac) operon domains in pGEM -Teasy plasmid from 
Promega (USA) and antigen genes are fused in-frame with the 5' domain of the β-
galactosidase alpha gene fragment and expression is under the lac promoter 
(Chin‟ombe, 2007; Chin‟ombe et al., 2009a, b). To achieve the first objective, the 
plasmid backbone (designated pGEM) for inserting the tat, nef and rt genes was 
generated. A recombinant plasmid, pGEM+SalmgagGFP, which contained the HIV-
1 gag and gfp genes fused in-frame with the β-galactosidase alpha gene fragment, 
was initially digested with HindIII and the ends filled-up by the addition of pfu DNA 
polymerase and dNTPs. The addition of pfu DNA polymerase and dNTPs resulted in 
the blunting of the HindIII-generated sticky ends. The gag gene was removed from 
the plasmid backbone by digestion with NarI. The plasmid backbone at this stage 
now contained sticky and blunt ends and the tat, nef and rt genes were successfully 
cloned uni-directionally into the pGEM backbone after digestion from pScript+Tat, 
pScript+Nef and pScript+RT, respectively using NarI and HpaI. DNA sequencing of 
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confirmed that the tat, nef and rt genes were successfully cloned in-frame with the 5' 
domain of the β-galactosidase alpha gene and were under the lac promoter.  
 
2.6.2 Expression of Tat, Nef and RT proteins in Salmonella enterica serovar 
Typhimurium 
An attenuated Salmonella enterica serovar Typhimurium was transformed using the 
recombinant plasmids (pGEM+Tat, pGEM+Nef, pGEM+RT) and the expression of 
Tat, Nef and RT proteins was evaluated. The Tat, Nef and RT proteins were the most 
highly expressed bacterial proteins by the recombinant Salmonella enterica serovar 
Typhimurium as their protein bands were visible on Coomassie-stained SDS-PAGE 
gels. The expression of Nef and RT by the recombinant Salmonella enterica serovar 
Typhimurium was further confirmed by Western blotting. The high-level expression 
of Tat, Nef and RT was in line with what was found in the previous studies by 
Chin‟ombe and colleagues (Chin‟ombe et al., 2009a). In these previous studies high 
levels of HIV-1 Gag, GFP and Gag-GFP were successfully expressed in attenuated 
Salmonella enterica serovar Typhimurium (Chin‟ombe, 2007; Chin‟ombe et al., 
2009a, b). These previous reports together with findings in this study show that 
Salmonella, just like E. coli, may be used for recombinant antigen expression.  
 
A number of factors, most of which were previously addressed by Chin‟ombe, 
(2007) and colleagues, played a role in facilitating the high level expression of HIV-
1 subtype C Tat, Nef and RT proteins in this study. These factors included gene 
codon optimization, fusion of the genes with the LacZa gene and the properties of the 
pGEM plasmid backbone. The codon optimization of the HIV-1 subtype C Tat, Nef 
and RT genes probably played a role in improving their expression by the Salmonella 
mutant. Several studies have shown that codon-optimization of heterologous genes 
improved their expression in bacterial systems (Apeler et al., 1997; Hu et al., 2006; 
Hu et al., 1989; Lakey et al., 2000; Makoff et al., 1989; Yadava and Ockenhouse, 
2003). The fusion of Tat, Nef or RT antigens to the E coli -galactosidase -
fragment facilitated their high-level expression. In previous studies, HIV-Gag and 
GFP were expressed at higher levels than unfused Gag and GFP in recombinant 
Salmonella expression system (Chin‟ombe, 2007). Other E. coli transcription and 
translation domains in the pGEM backbone such as transcription initiation, 
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binding site were also recognized by the Salmonella bacteria and played some role in 
facilitating the expression of the Tat, Nef and RT proteins (Brown et al., 1990; Poole 
et al., 1995).  
Recent studies by Chin‟ombe et al. (2009a,b) showed that recombinant Salmonella 
enterica serovar Typhimurium expressing high levels of GFP and Gag antigens 
induced GFP specific CD8+ T cell responses and HIV-1 subtype C Gag specific cell 
mediated (CD4+ Th1 and Th2) responses in vaccinated mice. Salmonella enterica 
serovar Typhimurium expressing Gag antigen also induced HIV-1 subtype C Gag 
specific antibody responses in the sera of vaccinated mice (Chin‟ombe et al., 2009b). 
Therefore, the developed Salmonella enterica serovar Typhimurium expressing high 
levels of HIV-1 subtype C Tat, Nef and RT antigens in the current study may be used 
in future studies for the evaluation of immune responses in vaccinated mice.  
 
The fact that the HIV-1 antigens in this study were expressed at very high levels, 
suggests that an attenuated recombinant Salmonella can potentially be used as a 
heterologous protein expression system for these proteins. Despite high levels of 
expression, the proteins could not be purified easily. Therefore, the decision was 
made to use His-tagged proteins for the development of Western blot to detect 
antibodies to HIV-1 subtype C infected individuals. This is described in Chapter 3 
and 4.  
 
In conclusion, HIV-1 subtype C tat, nef and rt genes were cloned and expressed at 
high levels in a  attenuated strain of Salmonella enterica serovar Typhimurium. The 
recombinant Salmonella bacteria could be used as vehicles for delivery of the HIV-1 
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CHAPTER 3 
PURIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 
SUBTYPE C TAT, NEF AND REVERSE TRANSCRIPTASE FROM 
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3.1 INTRODUCTION 
A number of expression systems are currently available for the production of 
recombinant proteins. They include bacterial, yeast, fungal, baculovirus and 
mammalian expression systems (Rai and Padh, 2001; Schmidt, 2004; Terpe, 2006). 
Bacterial expression systems, especially the Escherichia coli bacterium, are used 
extensively because of their advantageous properties (Hannig and Makrides, 1998; 
Jana and Deb, 2005; Sørensen and Mortensen. 2005). They can easily be cultured in 
a laboratory and grow rapidly to reach high biomass in a short period of time (Chen 
et al., 2006; Langlais et al., 2007; Terpe, 2006). They can be grown using cheaply 
available media (Terpe, 2006). The molecular biology of most bacterial systems is 
well-characterized and they can therefore easily be manipulated (Chen et al., 2006; 
Langlais et al., 2007; Terpe, 2006). There are many expression plasmid vectors 
available commercially which can be used for the cloning f foreign genes (Langlais 
et al., 2007). There are some disadvantages of using bacteria as heterologous protein 
expression systems (Terpe, 2006). Proteins expressed in bacteria do not have post-
translational modifications such as glycosylation. When over-expressed in bacteria, 
some foreign proteins form misfolded aggregations called inclusion bodies (Ventura 
and Villaverde, 2006). Foreign genes may also contain rare codons and may 
therefore need to be codon-optimized for optimal expression in bacteria (Das et al., 
2009). 
 
To facilitate the purification of recombinant proteins or antigens from bacterial 
expression systems, affinity tags such as Histidine tag (His-tag), arginine-tag (Arg-
tag), glutathione S-transferase tag, calmodulin-binding tag, cellulose-binding domain 
and maltose-binding protein are normally used (Hochuli et al., 1988; Hopp et al., 
1988; Sassenfeld and Brewer, 1984; Smith and Johnson, 1988; Stofko-Hann et al., 
1992; Terpe, 2003). The His-tag is the most extensively used affinity tag for 
purification of foreign proteins expressed in bacterial systems (Terpe, 2003). His-
tags are tandem repeats of 2-10 Histidine residues (usually 6) whose coding 
sequences are cloned in-frame to the gene to be expressed in the bacterial system. 
They efficiently bind to immobilized nickel nitrotriacetic acid (Ni-NTA) resins 
(Porath et al., 1975; Siddappa et al., 2006). His-tagged foreign proteins can therefore 
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2002). The His-tagged proteins bind to the immobilized Ni-NTA resins and can be 
eluted from the columns using specific buffers such as 20-250 mM imidazole (Hefti 
et al., 2001; Rank et al., 2002). His-tags can be fused at the C-terminus or N-
terminus of the protein to be purified (Hochuli et al., 1988).  
 
Although E. coli has been used extensively to produce foreign viral proteins, the 
closely-related bacteria such as Salmonella have not been investigated as potential 
heterologous expression systems. Since it has already been shown that HIV-1 Tat, 
Nef and RT proteins could be expressed at very high levels in recombinant 
Salmonella enterica serovar Typhimurium (Chapter 2), it was evident that the 
proteins could also be purified from the bacteria. The expressed HIV-1 Tat, Nef and 
RT proteins (Chapter 2) were required to be fused to an affinity purification tag such 




The objective of this study was to purify the human immunodeficiency virus type 1 
subtype C Tat, Nef and RT proteins previously expressed in recombinant Salmonella 
enterica serovar Typhimurium (Chapter 2). In order to purify the recombinant HIV-1 
Tat, Nef and RT antigens from the bacteria, they (Tat, Nef and RT) were supposed to 
have the affinity purification His-tag. Recombinant expression plasmids which 
already contained tat, nef and rt genes fused to the His-tag coding sequences were 
therefore used. The plasmid constructs were pGEM+hisTat, pGEM+hisNef and 
pGEM+hisRT and contained tat, nef and rt genes cloned from pScript+Tat, 
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3.3 MATERIALS  
The plasmids which contained the HIV-1 subtype C tat, nef and rt genes fused to the 
His-tag coding sequence were provided by Dr N Chin‟ombe (University of Cape 
Town). They were pGEM+hisTat, pGEM+hisNef and pGEM+hisRT (Figure 3.1 A- 
C) and they contained tat, nef and rt genes fused to the His-tag coding sequences to 
facilitate purification. The pGEM+hisGFP plasmid which contained His-tagged gfp 
gene was also provided by Dr Chin‟ombe. The plasmids were previously made by 
our research group (Lebeko, 2007). Special solutions and buffers used in this study 
are given in the Appendix A. 
 
Figure 3.1: Maps of HIV-1 subtype C tat, nef and rt expression plasmids 
(pGEM+hisTat, pGEM+hisNef and pGEM+hisRT), constructed by DNAMAN 
software version 4.0 (Lynnon Biosoft, Canada) and were used in this study. The 
genes were previously cloned into the pGEM backbone and were fused in frame with 
the β-galactosidase α-gene (lacZa) and the His-tag. The expression of the fusion 
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3.4 METHODS 
3.4.1 Restriction mapping of pGEM+hisTat, pGEM+hisNef and pGEM+hisRT 
The pGEM+hisTat, pGEM+hisNef, and pGEM+hisRT plasmids which were 
provided were mapped to confirm the presence of the His-tagged HIV-1 tat, nef and 
rt genes. The plasmids were mapped using NotI and NdeI restriction enzymes. The 
digestion was done in a total volume of 20 µl and it contained 500 ng of plasmid 
DNA, 2X of 10X restriction buffer (Roche Diagnostics, Germany), 2 U of enzyme/s. 
The digestions were incubated at 37 C for 2 hrs and the resulting DNA fragments 
were analysed by 1.5% agarose electrophoresis.  
 
3.4.2 Expression of His-tagged HIV-1 Tat, Nef and RT in recombinant 
Salmonella enterica serovar Typhimurium 
Competent Salmonella enterica serovar Typhimurium cells were transformed with 
pGEM+hisTat, pGEM+hisNef, and pGEM+hisRT as previously described (Chapter 
2). Total bacterial proteins containing His-tagged Tat, Nef and RT were extracted as 
previously described (Chapter 2, section 2.4.9). The protein samples were evaluated 
using the 12.5% SDS-PAGE as previously described (Chapter 2, section 2.4.11). A 
spectrum broad range colour stained marker (Bio-Rad, Canada) was loaded to 
identify the protein sizes. The expression of His-tagged Tat, Nef and RT was 
confirmed by Western blotting with mouse penta anti-His primary antibody 
(QIAGEN, Germany) at a 1: 500 dilution as previously described (Chapter 2, section 
2.4.12 – 2.4.13). The expression of Nef and RT proteins was confirmed with mouse 
anti-Nef (Sigma, Germany) and rabbit anti-RT (Sigma, Germany) antibodies diluted 
1: 1000. The primary mouse anti-His and anti-Nef antibodies were detected with 
secondary goat anti-mouse IgG antibody conjugated to alkaline phosphatase (Sigma, 
Germany) and rabbit anti-RT antibody was detected with goat anti-rabbit IgG 
secondary antibody conjugated to alkaline phosphatase (Sigma, Germany). The total 
Salmonella enterica serovar Typhimurium extracts previously expressed Tat, Nef 
and RT proteins with no His-tag were used as controls. The total Salmonella extracts 
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3.4.3 Purification of HIV-1 Tat, Nef and RT antigens under denaturing 
conditions 
The His-tagged Tat, Nef and RT recombinant proteins were purified from 
recombinant Salmonella enterica serovar Typhimurium using Ni-NTA nickel chelate 
affinity chromatography. Briefly, the Salmonella enterica serovar Typhimurium 
were transformed with pGEM+hisTat, pGEM+hisNef, and pGEM+hisRT plasmids 
and grown as previously described (Chapter 2, section 2.4.8). Two volumes of 
bacterial culture (100 ml each) were pelleted at 5000 rpm (Sorvall RC-5C Plus 
superspeed centrifuge, Rotor S/N 10300651, USA) for 15 min at 4oC. The pellets 
were washed with 50 ml cold PBS (pH 7.4) at 10000 rpm (Sorvall RC-5C Plus 
superspeed centrifuge, Rotor S/N 10300651, USA) for 30 min. One pellet was kept 
at 4
o
C for purification of proteins under native conditions (Sectio  3.4.4) and another 
pellet was resuspended in 10 ml of denaturing lysis buffer (Appendix A: 38).  
 
The cell suspension was incubated at room temperature for 60 min and swirled at 15 
min intervals. The cell lysates were centrifuged at 12000 rpm (Sorvall RC-5C Plus 
superspeed centrifuge, Rotor S/N 10300651, USA) for 30 min at 24
o
C to pellet the 
cellular debris and 10 ml supernatant was collected for affinity purification. The Fast 





agarose buffer (QIAGEN, Germany) and 10 ml 
supernatant was applied to the column. The column was washed twice with 4 ml 
denaturing wash buff r (Appendix A: 39). The protein fraction was eluted seven 
times with 400 µl denaturing elution buffer (Appendix A: 40). The His-tagged GFP 
protein was also purified in parallel with Tat, Nef and RT proteins under denaturing 
conditions and served as a control. Samples were collected at each stage of the whole 
process for future SDS-PAGE analysis and Western blotting.  
 
3.4.4 Purification of HIV-1 Tat, Nef and RT antigens under native condition 
The Tat, Nef and RT proteins were also purified under native conditions using the 
same technique, Ni-NTA nickel chelate affinity chromatography. The His-tagged 
GFP protein was purified in parallel with Tat, Nef and RT proteins, respectively and 
served as a purification control. Briefly, the frozen pellets prepared from above 
(section 3.4.3) were thawed for 10 min at room temperature and resuspended in 10 
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cell lysate was centrifuged at 12000 rpm (Sorvall RC-5C Plus superspeed centrifuge, 
Rotor S/N 10300651, USA) for 30 min at 4
o
C to pellet the cellular debris and 10 ml 
supernatant was collected for affinity purification. The Fast start Column (QIAGEN, 
Germany) was prepared by incubation with 400 µl NTA agarose buffer (QIAGEN, 
Germany) and 10 ml supernatant was applied to the column. The column was 
washed twice with 4 ml of native wash buffer (Appendix A: 42). The protein fraction 
was eluted seven times with 400 µl of native elution buffer (Appendix A: 43). At 
each stage, samples were collected for future SDS-PAGE and Western blotting.  
 
3.4.5 Quantification of purified HIV-1 Tat, Nef and RT proteins 
The fraction samples were quantified using the Nanodrop DC-1000 UV/VIS 
spectrophotometer (Thermo Scientific, USA) and BSA standard curves as described 
earlier (Chapter 2, section 2.5.14). 
 
3.4.6 SDS-PAGE and Western blotting analysis of purified HIV-1 Tat, Nef and 
RT proteins  
The purity of each of the HIV-1 Tat, Nef and RT proteins was evaluated using 12.5% 
SDS-PAGE and Western blotting. Twenty microlitres of each fraction was mixed 
with an equal amount of protein loading buffer and 15 µl of each fraction was loaded 
on 12.5% SDS-PAGE. A multicolour broad range protein marker (Fermentas, 
Canada) was loaded for identification of the protein bands. The proteins were 
electroblotted to a PVDF membrane (Amersham, UK) as previously described 
(Chapter 2, section 2.4.13). The blots were incubated in blocking buffer (Appendix 
A: 30) as previously described and purified HIV-1 Tat, Nef and RT proteins were 
detected with mouse penta anti-His primary antibody (QIAGEN, Germany) diluted 
1: 500 as previously described (Chapter 2, section 2.4.14). The blots were incubated 
in goat anti-mouse IgG alkaline phosphatase-linked secondary antibody (Sigma, 
Germany) diluted 1: 10000 as previously described (Chapter 2, section 2.4.14). The 
blots were developed using NBT/BCIP (Roche Diagnostics, Germany) and scanned 
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3.5 RESULTS 
3.5.1 Verification of pGEM+hisTat, pGEM+hisNef and pGEM+hisRT  
The presence of HIV-1 tat, nef and rt genes in pGEM+hisTat, pGEM+hisNef and 
pGEM+hisRT was confirmed by restriction mapping. The plasmids contained HIV-1 
tat, nef and rt genes between the NotI and NdeI sites. The previously constructed 
pGEM+Tat, pGEM+Nef and pGEM+RT plasmids (Chapter 2) which contained the 
HIV-1 genes between EcoRI were used as controls. The expected sizes of the gene 
fragments after restriction digestion were observed (Table 3.1, Figures 3.2 A-C). 
 
Figure 3.2: Restriction mapping of pGEM+hisTat, pGEM+hisNef and pGEM+hisRT 
plasmids using NotI and NdeI. (A) A pGEM+hisTat and pGEM+Tat. Lane 1: O‟Generuler 
100 bp DNA ladder, Lane 2: pGEM+hisTat, Lane 3: pGEM+Tat (control). (B) A 
pGEM+hisNef and pGEM+Nef.  Lane 1: O‟Generuler 100bp DNA ladder, Lane 2: 
pGEM+hisNef, Lane 3: pGEM+Nef (control). (C) A pGEM+hisRT and pGEM+RT. Lane 
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Table 3.1: The expected bands of pGEM+hisTat, pGEM+hisNef and pGEM+hisRT 
after restriction mapping  
Plasmid Name Restriction Enzymes Expected DNA band sizes 
(bp) 
pGEM+hisTat NotI and NdeI 403  and 2980 
pGEM+Tat  EcoRI 429 and 2997 
pGEM+hisNef NotI and NdeI 629 and 2941 
pGEM+Nef  EcoRI 655 and 2997 
pGEM+hisRT NotI and NdeI 1355 and 2980 
pGEM+RT  EcoRI 1381 and 2997 
 
 
3.5.2 Expression of His-tagged Tat, Nef and RT in Salmonella enterica serovar 
Typhimurium 
Recombinant Salmonella enterica serovar Typhimurium was transformed with 
pGEM+hisTat, pGEM+hisNef and pGEM+hisRT plasmids for expression. Total 
Salmonella proteins containing His-tagged Tat, Nef and RT, respectively, were 
extracted. The expression of His-tagged Tat, Nef and RT proteins was analysed by 
SDS-PAGE and Western blotting. The total Salmonella protein extracts expressing 
non-tagged Tat, Nef and RT proteins, respectively, were used as controls. The 
protein bands for Tat, Nef and RT proteins were visible on the Coomassie-stained 
SDS-PAGE gels (Figure 3.2A, Figure 3.3A and Figure 3.4A).  
 
The penta anti-His antibody recognizes an epitope comprising five consecutive 
Histidine residues. Western blot analysis with this antibody detected only His-tagged 
Tat, Nef and RT proteins (Figure 3.2B, lane 2; Figure 3.3B, lane 2 and Figure 3.4B, 
lane 2). As expected, non-tagged (Tat, Nef and RT) proteins and total Salmonella 
extracts carrying an empty plasmid were not seen on the Western blots (Figure 3.2B, 
lanes 3 & 4; Figure 3.3B, lanes 3 & 4 and Figure 3.4B, lanes 3 & 4). The anti-Nef 
and anti-RT antibodies detected Nef and RT respectively (Figure 3.3C, lanes 2 & 3  
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antibody. His-tagged Tat, Nef and RT proteins were observed with expected 
molecular weights of 20 kDa, 29 kDa and 58 kDa, respectively.   
 
Figure 3.2:  The expression of the His-tagged Tat protein by recombinant Salmonella 
enterica serovar Typhimurium. A is a Coomassie-stained SDS-PAGE gel and B is a 
Western blot with Tat protein detected with anti-His antibody. Lane 1: Marker, Lane 2: 
Salmonella expressing His-tagged Tat, Lane 3: Salmonella expressing non-tagged Tat 



















Figure 3.3:  The expression of the His-tagged Nef protein by recombinant Salmonella 
enterica serovar Typhimu ium. A is a Coomassie-stained SDS-PAGE gel, B is a Western 
blot with Nef protein detected with anti-His antibody and C is a Western blot with Nef 
proteins detected with anti-Nef antibody. Lane 1: Marker, Lane 2: Salmonella expressing 
His-tagged Nef, Lane 3: Salmonella expressing non-tagged Nef (control), Lane 4: 
























Figure 3.4:  The expression of the His-tagged RT protein by recombinant Salmonella 
enterica serovar Typhimurium. A is a Coomassie-stained SDS-PAGE gel, B is a Western 
blot with RT protein detected with anti-His antibody and C is a Western blot with RT 
proteins detected with anti-RT antibody. Lane 1: Marker, Lane 2: Salmonella expressing 
His-tagged RT, Lane 3: Salmonella expressing non-tagged RT (control), Lane 4: Salmonella 
carrying an empty plasmid (control).  
 
 
3.5.3 Purification His-tagged Tat, Nef and RT from Salmonella enterica serovar 
Typhimurium 
The pGEM+hisTat, pGEM+hisNef and pGEM+hisRT plasmids were transformed 
into Salmonella enterica serovar Typhimurium for purification. His-tagged Tat, Nef 
and RT were purified under denaturing and native conditions using nickel chelate 
affinity chromatography with Ni-NTA agarose (QIAGEN, Germany). A 28 kDa GFP 
protein was also transformed in Salmonella enterica serovar Typhimurium and used 
as a positive purification control for Tat, Nef and RT, respectively. The concentration 
of the purified recombinant protein was determined by BSA standard curve. A 500 
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Tat, Nef and RT proteins, respectively, were obtained by purification under 
denaturing conditions.  
 
The purity and detection sensitivity of the purified recombinant Tat, Nef, RT and 
GFP (positive control) proteins were estimated following visualization on SDS-
PAGE and Western blot. Coomassie-stained SDS-PAGE gels showed that 
recombinant GFP (positive control) was purified under both denaturing and native 
conditions (Figure 3.5 A-B, lanes 6-10). Nef protein was also purified under both 
denaturing and native conditions (Figure 3.6 A-B, lanes 6-10). Recombinant Tat and 
RT were purified under denaturing (Figure 3.7 A, lanes 6-8 and Figure 3.8 A, lanes 
6-8) but not under native condition (Figure 3.7 B, lanes 6-8 and Figure 3.8 B, lanes 
6-8). The purification of heterologous RT protein probably due to its high molecular 
weight was not as simple as of recombinant Tat, Nef and GFP proteins. The RT 
protein failed to be eluted with denaturing elution buffer adjusted to pH 4.5 as 
compared to Tat and Nef according to manufacturer‟s instructions (QIAGEN, 
Germany).   
 
Western blot analyses with anti-His antibody showed that purified Nef and GFP 
(purification positive control) were detected in all elution fractions under denaturing 
and native conditions (Figure 3.5 C and D, lanes 6-10 and Figure 3.6 C and D, lanes 
6-10) whereas purification of Tat and RT under denaturing conditions were detected 
only in elution fractions 1-3 (Figure 3.7C, lanes 6-8 and Figure 3.8C, lanes 6-8). 
Highest quantities of proteins were obtained in elution fraction 2 for Tat, Nef and 
GFP (Figure 3.5C, lane 7, Figure 3.6C, lane 7 and Figure 3.7C, lane 7) and elution 
fraction 1 for RT (Figure 3.7C, lane 6) purification under denaturing conditions. The 
purity of the proteins seemed to depend on the elution time points and protein 
quantities. There were extra bands observed under or below the bands representing 
Tat, Nef, RT and GFP proteins and these extra bands appeared mostly on the elution 
fractions containing the highest level of proteins purified under denaturing conditions 
(Figures 3.5C, 3.6C, 3.7C, lanes 7 and Figure 3.8C, lane 6). The expected molecular 
weights of Tat, Nef and RT proteins were 20 kDa, 29 kDa and 58 kDa, respectively 
and they seemed to be achieved except where the bands were skewed due to poor 
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Figure 3.6 B and D (lanes 6-10). The DNA and protein sequence of His-tagged Tat, 




Figure 3.5:  Purification of recombinant GFP from Salmonella enterica serovar 
Typhimurium. (A & B) Coomassie-stained SDS-PAGE showing GFP purified under (A) 
denaturing conditions and (B) native conditions. (C & D) Western blot showing GFP 
purified under (C) denaturing conditions and (D) native conditions. Lane 1: Protein marker, 
Lane 2: CL (Cell Lysates), Lane 3:  FL (Flow Through) Lane 4:  W1 (Wash 1) Lane 5: 
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Figure 3.6:  Purification of recombinant Nef from Salmonella enterica serovar 
Typhimurium. (A & B) Coomassie-stained SDS-PAGE showing Nef purified under (A) 
denaturing conditions and (B) native conditions. (C & D) Western blot showing Nef purified 
under (C) denaturing conditions and (D) native conditions. Lane 1: Protein marker, Lane 2: 
CL (Cell Lysates), Lane 3:  FL (Flow Through) Lane 4:  W1 (Wash 1) Lane 5: W2 (Wash 
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Figure 3.7:  Purification of recombinant Tat from Salmonella enterica serovar 
Typhimurium. (A & B) Coomassie-stained SDS-PAGE showing Tat purified under (A) 
denaturing conditions and (B) native conditions. (C & D) Western blot showing Tat purified 
under (C) denaturing conditions and (D) native conditions. Lane 1: Protein marker, Lane 2: 
CL (Cell Lysates), Lane 3:  FL (Flow Through) Lane 4:  W1 (Wash 1) Lane 5: W2 (Wash 
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Figure 3.8:  Purification of recombinant RT from Salmonella enterica serovar 
Typhimurium. (A & B) Coomassie-stained SDS-PAGE showing RT purified under (A) 
denaturing conditions and (B) native c nditions.(C & D) Western blot showing RT purified 
under (C) denaturing conditions and (D) native conditions. Lane 1: Protein marker, Lane 2: 
CL (Cell Lysates), Lane 3:  FL (Flow Through) Lane 4:  W1 (Wash 1) Lane 5: W2 (Wash 
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3.6 DISCUSSION 
Recombinant HIV-1 Tat, Nef and RT proteins were previously expressed 
successfully at very high levels in recombinant Salmonella enterica serovar 
Typhimurium (Chapter 2). The expressed proteins could not be purified because they 
did not have purification tags such as the His-tag. In this study, the HIV-1 subtype C 
Tat, Nef and RT proteins which contained the His-tag were successfully purified 
from the recombinant Salmonella enterica serovar Typhimurium expressing them. 
The pGEM+hisTat, pGEM+hisNef and pGEM+hisRT were previously constructed 
(Lebeko, 2007) so that the coding sequences of the His-tag was fused in-frame 
between the lacZα and HIV-1 tat, nef or rt genes (Lebeko, 2007). The presence of the 
HIV-1 tat, nef or rt genes in the pGEM+hisTat, pGEM+hisNef and pGEM+hisRT 
respectively, was confirmed by restriction mapping using NotI and NdeI. This 
restriction mapping verified that the expected HIV-1 genes had previously been 
cloned into the given plasmids. 
 
3.6.1 Expression of His-tagged Tat, Nef and RT in Salmonella enterica serovar 
Typhimurium 
The pGEM+hisTat, pGEM+hisNef and pGEM+hisRT used to transform Salmonella 
enterica serovar Typhimurium and the expression of the HIV-1 Tat, Nef and RT was 
evaluated by SDS-PAGE and Western blotting. The protein bands of the three 
antigens were visible on the Coomassie blue-stained SDS-PAGE. This showed that 
the His-tagged HIV-1 antigens were most highly expressed Salmonella enterica 
serovar Typhimurium bacterial proteins. The intensities of the protein bands of the 
His-tagged HIV-1 antigens was almost the same as those of untagged HIV-1 ones. 
This suggested that the His-tag did not affect the expression of the HIV-1 antigens in 
recombinant Salmonella. Since the His-tag used in this study was small (only 6 
Histidine residues), any negative impact on Tat, Nef or RT expression by the bacteria 
was anticipated. The expressed HIV-1 antigens were detected by the penta anti-His 
antibody in a Western blotting assay. This showed that the penta anti-His antibody 
(which recognizes any five consecutive Histidine residues) was able to bind to the 
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3.6.2 Purification of His-tagged Tat, Nef and RT from Salmonella enterica 
serovar Typhimurium 
The successful purification of proteins from recombinant bacteria depends mainly on 
whether their solubility, their localization and the accessibility of the His-tag. In most 
cases, proteins expressed in gram-negative bacteria such as E. coli or Salmonella 
form insoluble aggregations called inclusion bodies (Carrio et al., 2001; LaVallie et 
al., 1993; Makrides, 1996; Rattenholl et al., 2001) and are difficult to purify. To 
successfully purify them, they have to be solubilised first using denaturants such as 
urea. In this study, the HIV-1 subtype C Tat, Nef and RT expressed from 
recombinant Salmonella enterica serovar Typhimurium were purified under both 
denaturing and native conditions using nickel chelate affinity chromatography. All 
the expressed antigens including GFP were successfully purified under denaturing 
conditions. However, only the GFP and the HIV-1 Nef were successfully purified 
under native conditions. This showed that a fraction of the expressed GFP and Nef 
was soluble and much of it was expressed as inclusion bodies and be solubilised 
under denaturing conditions with denaturant, urea. The failure to purify HIV-1 Tat 
and RT in this study suggested that they were predominantly expressed as inclusion 
bodies by the bacteria.  
High levels of purified protein were obtained for Tat (375 µg) and Nef (450 µg) 
compared to RT (300 µg). Elution conditions for RT were changed from pH 4.5 to 
pH 3.7 and the protein was eluted in the first elution fraction whereas Tat and Nef 
were eluted in the second fraction. RT protein is a large protein of molecular weight 
of about 58 kDa and perhaps pH of 4.5 was too high to break down the bonds 
between the Ni-NTA and the His-tag to release the RT protein (QIAGEN 
purification kit booklet, Germany). The purity of the protein seemed to depend on the 
elution time points and quantity of recombinant Tat, Nef and RT proteins. There 
were non-specific bands observed in elution fractions during purification under 
denaturing condition and these were abundant in the highly concentrated elution 
fractions. This may represent contaminants associated with too much use of Ni-NTA 
matrix, His-tagged or truncated forms of His-tagged proteins, improper washing 
during purification, or proteolytic degradation products of the recombinant proteins 
in Salmonella bacteria. However, low concentration of imidazole (10 mM to 20 mM) 
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reducing the amount of contaminating proteins. Reduction of the amount of Ni-NTA 
magnetic agarose beads, addition of protein inhibitors such as PMSF and keeping the 
protein buffers at 0-4ºC may also be necessary to prevent protein degradation 
(Schmitt et al., 1993).    
 
The results in this study were in line with previous findings in which HIV-1 Tat, Nef 
and RT proteins were purified from E. coli (Lebeko, 2007). It was shown that Tat 
and RT were purified only under denaturing conditions while Nef was purified under 
both denaturing and native conditions (Lebeko, 2007). In other studies, GFP and 
human proteins, Tat, Nef and RT labelled with His-tag were successfully purified 
from E. coli under denaturing conditions (Federico et al., 2001; LcGrice and 
Grüninger-Leitch, 1990; Ma et al., 2006a; Park et al., 2002; Woestenenk et al., 
2004). The GFP, Nef and Kinesin were also labelled with His-tag and purified under 
native conditions from E. coli (Blanc et al., 1999; Finzi et al., 2003; Gibert et al., 
2000; Marusic et al., 2007; Seleem et al., 2008). The GFP was also successfully 
purified under denaturing conditions from Salmonella enterica serovar Typhimurium 
(Seleem et al., 2008).  
 
In conclusion, high amounts of HIV-1 subtype C Tat, Nef and RT, which were 
mainly expressed as inclusion bodies, were purified from recombinant Salmonella 
enterica serovar Typhimurium under denaturing conditions. The purified proteins 
were useful as reagents in immunoassays for the detection of HIV-1 antibodies in 
clinical specimens (Chapter 4) or in animals vaccinated with HIV-1 vaccines 
(Chapter 5). The purified HIV-1 subtype C Tat, Nef and RT recombinant proteins 
can also be used to develop protein-based (subunit) vaccines for induction of 
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4.2 INTRODUCTION 
Humoral responses to HIV-1 infection lead to the production of antibodies against 
the virus. This process is aided by type 2 cytokines which are thought to enhance the 
humoral antibody responses in HIV infected individuals (Clerici and Shearer, 1996; 
Romagnani et al., 1995; Swain et al., 1991). Neutralizing antibodies target the HIV 
envelope where  they usually recognize the V3 loop of gp120, the CD4 binding sites 
and glycoprotein gp41 protein (Letvin and Walker, 2003; Parren and Burton, 2001). 
However, it should be noted that nearly 50% of the molecular weight of the envelope 
gp120 is covered with carbohydrate mannoses (glycan shield) that mask important 
epitopes from being recognised by neutralizing antibodies (Balzarin et al., 2005; 
Reitter et al., 1998). The CD4 binding sites and gp41 domains are highly conserved 
and antibodies to these sites recognise different HIV-1 subtypes (Letvin and Walker, 
2003; Trkola et al., 1995). 
 
Sera from HIV-infected individuals in South Africa and Uganda have been observed 
to neutralise different HIV-1 subtypes (Fanales-Belasio et al., 2002b). However, 
neutralizing antibodies may also bind weakly to CD4 binding sites and thus fail to 
neutralize the HIV infection (Wu et al., 2009 Neutralizing antibodies have little or no 
effect on HIV-1 replication once the viral binding and fusion with the plasma 
membrane of the target cell has occurred (Clerici and Shearer, 1996; Letvin and 
Walker, 2003; Wu et al., 2009). Published studies by Carotenuto et al. (1998) and 
Pilgrim et a1. (1997) showed that broadly neutralizing antibodies protected long-
term non-progressors against AIDS by delaying the disease progression as compared 
to rapid disease progressors. Another study reported that high neutralizing antibody 
titers in mothers may reduces the risks of mother-to-child HIV-1 transmission 
(Colgnesi et al., 1997; Kliks et al., 1994). 
 
HIV infection induces the production of humoral antibodies in response to HIV 
proteins including structural and regulatory proteins (Letvin et al., 1985). Humoral 
(both binding and neutralizing) antibodies may or may not lead to killing the virus 
(Clerici and Shearer, 1996). Neutralizing antibodies play an important role in 
establishing the viral containment in HIV exposed individuals, especially if they are 
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responses would be a good target for the development of prophylactic vaccine. This 
is supported by two findings; (1) antibody responses have been elicited and 
correlated with the effectiveness of commercially licensed vaccines such as those for 
measles, mumps and rubella (Marin et al., 2007; Vesikari et al., 2004) and (2) 
specific anti-SHIV antibodies associated with protection against SHIV infection were 
observed in non-human primates (Belliard et al., 2005).  
The ELISA, RIA and Western blot assays are useful for evaluating the natural 
binding antibody responses to HIV (Bahraoui et al., 1990; Chen et al., 1999; 
Demirhan et al., 1999). Indicated by a number of clinical studies, these techniques 
detected HIV-1 antibodies against viral proteins such as structural (Gag, Pol and 
Env), regulatory (Tat and Rev) and accessory (Nef, Vif, Vpr and Vpu) proteins in a 
cohort of HIV-1 infected individuals (Chen et al., 1999; Chou et al., 1990; Lange et 
al., 1986; Matsuda et al., 1988; Reiss et al., 1990). Although antibodies to regulatory 
proteins are less quantitavely detected as compared to structural proteins, there is 
evidence that they may elicit the antibody responses (Allan et al., 1985; Chen et al., 
1999; Lange et al., 1986; Keet et al., 1994; Kühn et al., 1987). In an early study, 
Reiss et al. (1990) reported that low antibody response against regulatory proteins is 
associated with rapid disease progression after HIV-1 infection. It should be noted 
that this may be a marker of a lack of HIV control and not the actual cause of disease 
progression. 
 
Binding antibody responses to core proteins such as Gag p24 and Gag p17 are 
detected in high prevalence in the sera of HIV-infected individuals (Chen et al., 
1999; Lange et al., 1986; Keet et al., 1994). In contrast, antibodies to Tat, Nef and 
RT have been detected in lower prevalence and less frequently in the sera of 
individuals. However, antibodies to Tat and Nef antigens were associated with slow 
progression to AIDS (Chen et al., 1999; Reiss et al, 1990), suggesting the possibility 
of using the detection of these antibodies as a marker of HIV disease progression. 
Published studies showed that AIDS occurred mostly in individuals who were 
negative for anti-Nef and anti-Tat antibodies as compared to individuals who were 
positive to these antibodies (Chen et al., 1999). However, these studies have been 
conducted in individuals infected with non-subtype C viruses. Similar studies using 
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associations occur among HIV-1 infected individuals in South Africa, where subtype 
C is the most prevalent subtype. 
 
4.2 OBJECTIVES 
Currently, no studies have been conducted on Tat, Nef or RT antibody responses in 
the sera of South African HIV-1 subtype C infected individuals. The HIV-1 Tat, Nef 
and RT play an important role in the viral life cycle and pathogenesis of the disease 
(Chang et al., 1994; Havlir et al., 1996; Wei et al., 2003). Acquiring increased 
knowledge on the detection of antibody responses to Tat, Nef and RT antigens in the 
sera of HIV-1 subtype C infected individuals could help to determine whether the 
presence of antibodies to these antigens can serve as marker of disease progression. 
In addition, the efficient presence of antibody responses to Tat, Nef and RT antigens 
would also determine whether these antigens could be included in diagnostic tools 
for HIV infection. Therefore, this study was aimed at investigating the prevalence of 
antibody responses to purified HIV-1 Tat, Nef and RT in the sera of HIV-1 subtype 
C infected individuals (Chapter 3) by employing Western blot assay. In addition, the 
study investigated whether the prevalence of these antibodies is associated with the 
clinical stage of the AIDS disease as defined by the level of CD4 cells count in the 









4.6.1 MATERIALS  
Serum samples were obtained from a clinical study which investigated the 
prevalence of genital HPV infection among HIV-1 infected and uninfected 
individuals (Mbulawa et al., 2009). The investigation was approved by the research 
ethics committee of the University of Cape Town. These individuals were tested at 
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centre, Cape town, SA) and gave their informed consent. Four- hundred and eighty 
one (481) serum samples were from HIV-1 infected males and females individuals 
aged between 17 and 65. Of these 481 samples, 124 pairs were from sexual partners. 
Some of the individuals had received antiretroviral therapy but the treatment record 
was unavailable as the records had not yet been transcribed into the central study 
database. All HIV positive individual in the study received a referral to the nearest 
ARV clinic to determine if they needed treatment.  An additional 20 serum samples 
from HIV-1 negative individuals, men and women served as negative controls. The 
samples were categorised into groups according to donor‟s CD4+ T cell count in 
peripheral blood and plasma HIV RNA load as given in Table 4.1. Group A (CD4: 
500 cells/µl or more) indicates healthy immune system, in spite of HIV-1 infection; 
Group B (CD4: 201 to 499 cells/µl) indicates damage of immune system due to HIV-
1 infection and Group C (CD4: 200 cells/µl or less) indicates the weakening of 
immune system and possible onset of AIDS (Mellors et al., 1997; Mylonakis et al., 
2001; Phair et al., 1990). All sera were heated at 56°C for 60 min to inactivate HIV 
(Spear et al., 1991). 
 
Table 4.1: Categories of sera samples into groups based on CD4+ T cell counts 
and plasma viral load 
CD4 category (cells no/µl) No of samples 
Group A: CD4 500 or more 115 
Group B: CD4 201 to 499 286 
Group C: CD4 200 or less 80 
Viral load category (RNA copies/ml) No of samples 
Group 1: VL 50 to 500 20 
Group 2: VL 501 to 5000 56 
Group 3: VL 5001 to 20, 000 77 
Group 4: VL 20, 001 or more 129 
4.6.1 METHODS 
4.6.2 Establishment of the best equivalent amounts of proteins 
In order to establish the optimum amount of each protein to load on the SDS-PAGE, 
molar equivalents of recombinant Tat, Nef and RT proteins previously purified 
(Chapter 3) were determined using the Promega BioMath program 
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achieve the best and equivalent banding pattern of all the proteins to eliminate the 
background reactivity that could arise during screening of the sera. Briefly, the 
purified proteins were serially diluted at four 2-fold concentrations and subjected to 
12.5% SDS-PAGE as previously described (Chapter 2, section 2.4.11). The proteins 
were transferred to the PVDF membrane (Amersham, UK) using electrophoretic 
blotting as previously described (Chapter 2, section 2.4.13). Recombinant Tat, Nef 
and RT proteins were detected with penta His-tag antibody as previously described 
(Chapter 2, section 2.4.14). After electroblotting, the SDS-PAGE gel was stained 
with Coomassie blue staining (Appendix A: 34) to allow the estimation of the 
transfer efficiency.  
4.6.2 Establishment of the best dilution of anti-human IgG alkaline 
phosphatase conjugate 
The best dilution of anti-human IgG alkaline phosphatase to detect the human sera 
was tested. Based on previous equimolar protein dilutions, two protein cocktails were 
prepared as follows: Cocktail 1 contained 0.022 µg Tat/well, 0.035 µg Nef/well & 
0.06 µg RT/well and the second quantity of  cocktail contained 0.011 µg Tat/well, 
0.18 µg Nef/well & 0.03 µg RT/well. The cocktails were migrated next to each other 
on 12.5% SDS-PAGE as previously described (Chapter 2, section 2.4.11). The 
proteins were electroblotted onto the PVDF membrane as previously described 
(Chapter 2, section 2.4.13) and the membrane was cut into strips. HIV positive 
control serum from New Lav Blot 1 commercial kit (Bio-Rad, Germany) was 
incubated with Salmonella (common gut pathogens) cell lysates overnight at 4⁰C to 
remove antibodies to Salmonella. The strips were incubated with HIV positive 
control serum at a dilution of 1:100 for 2 hrs with gentle shaking at room 
temperature. The strips were washed four times (10 min each) with washing buffer 
(Appendix 30) to remove unbound antibodies and incubated with polyclonal anti-
human IgG conjugated to alkaline phosphatase (Sigma, Germany) in various 
dilutions (1: 2000; 1: 4000; 1: 6000; 1: 8000 and 1: 10,000) for 60 min. The strips 
were washed as previously and developed with NBT-BCIP substrate solution for 15 
min. Reaction was then stopped by rinsing the strips with water. The strips were 
dried with paper towel and scanned (CannonScan 8000F, China). The intensity of the 
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experiments. The optimal dilution was selected based on the optimal band intensity 
for all antigens.   
 
4.6.2 Detection of HIV-1 Tat, Nef and RT antibodies in human sera by 
Western blot assay  
To detect the presence of HIV-1 Tat, Nef and RT antibodies in the sera of HIV-1 
infected individuals, a cocktail containing purified recombinant proteins (Tat, Nef 
and RT) was migrated on a 12.5% SDS-PAGE as previously described (Chapter 2: 
section 2.4.11). The molar equivalent amounts of each protein used for SDS-PAGE 
was as follows:  Tat (0.011 µg), Nef (0.018 µg) and RT (0.03 µg) as established in 
section 4.4.2. The proteins were transferred on to PVDF membranes as previously 
described (Chapter 2, section 2.4.13).  Following transfer, the PVDF membranes 
were incubated with 5% blocking buffer (Appendix A: 30) for 2 hrs at room 
temperature and left at -4⁰C on a shaker overnight. The membranes were dried and 
kept at 4⁰C until use. Before use in a Western blot assays, the sera were incubated 
with Salmonella cell lysates at dilution of 1:100 overnight at 4⁰C to remove the 
antibodies to Salmonella. The membranes were taken out of the fridge, cut into thin 
strips, labelled and soaked in methanol (for 2 min) and water for 5 min. After 
soaking, the strips were washed once for 10 min with washing buffer (Appendix A: 
30) and each strip was incubated with serum at a dilution of 1:100 at room 
temperature for 2 hrs. Samples from HIV negative donors were used as negative 
controls.  The strips were washed four times (10 min each) with washing buffer 
(Appendix 30) to remove unbound antibodies. The strips were then incubated with 
goat anti-human IgG conjugated to alkaline phosphatase (Sigma, Germany) at a 
dilution of 1:8000 (as established from the above section 4.4.2) for 60 min at room 
temperature. After incubation, the membranes were washed as before and the binding 
of the secondary antibody was detected with NBT-BCIP substrate solution (Roche 
Diagnostics, Germany) following the manufacturer‟s instructions. The reaction was 
allowed until 15 min and the strips were then rinsed with water, dried with paper 
towel, taped on white A4 paper and scanned (CanonScan 8000F, China).    
Each Western blot strip was scored by visual examination as negative or positive for 
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corresponding to the expected position of these antigens irrespective of the intensity 
of the reactive bands.  
 
The overall performance of the Western blot assay method in detecting antibodies to 
HIV was estimated by calculating the sensitivity and specificity using the following 
formulas: 
Sensitivity =    Number of positive samples to any of the 3 HIV proteins   X 100% 
                                                 Number of total samples from HIV positive donors             
Specificity =   Number of negative samples to any of the 3 HIV proteins   X 100%                                                      
                                            Number of total samples from HIV negative donors    
 
4.6.2 Statistical analysis 
Statistical analysis was performed using Computer software, Graph Pad Prism 
version 5.0 (La Jolla, California, USA). The data were tabulated by 2 x 2 
contingency tables to determine the p-values. A two-tailed Fisher‟s exact test (X2 – 
test) determined whether there was significant difference between the two or among 
three groups. Significance was measured to a 95% confidence interval with p-value 









4.6.2 Establishment of the best equivalent amounts of proteins to give 
reproducible Western Blots 
As previously described in section 4.2.1, the best molar equivalent amount of Tat, 
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RT proteins were clearly visualized by Coomassie blue staining on the SDS-PAGE 
(Figure 4.1, A-C). After electroblotting, the SDS-PAGE gel was also stained with 
Coomassie blue to estimate the transfer efficiency and the results showed that Nef 
and RT were almost completely transferred while some Tat protein remained on the 
stained SDS-PAGE gel after transfer (Figure 4.1, D - E). Western blots showed that 
Tat, Nef and RT proteins were strongly detected with penta anti-His-tag antibody at 
all dilutions (Figure 4.1, G - I). When further serial dilutions of Tat, Nef and RT 
were prepared in a cocktail format, clear banding patterns were observed for cocktail 
number 1 that  contained 0.022 µg Tat, 0.035 µg Nef & 0.06 µg RT and cocktail 
number 2 that contained 0.011 µg Tat, 0.018 µg Nef and 0.03 µg RT (Figure 4.2, 
Lane 2 & 3). Beyond these concentrations, bands corresponding to Tat, Nef and 
eventually to RT could not be visualized. Thus, the molar equivalent corresponding 
to 0.011 µg Tat, 0.018 µg Nef and 0.03 µg RT was chosen as the optimum amounts 
of proteins for cocktails in further Western blot assays.  This combination gave 
clearly visible band on Western Blot with a relatively low background. 
4.6.2 Establishment of the best dilution of anti-human IgG alkaline 
phosphatase conjugate 
Five strips bound with two cocktails (cocktail 1 contained 0.022 µg Tat, 0.035 µg 
Nef & 0.06 µg RT and cocktail 2 contained 0.011 µg Tat, 0.018 µg Nef and 0.03 µg 
RT) were prepared and used for establishment of optimal dilution of anti-human IgG 
alkaline phosphatase to detect IgG antibodies in human sera.  The Western blot assay 
showed that 1: 8000 dilution on the lane loaded a cocktail containing 0.022 µg, 0.035 
µg and 0.06 µg of Tat Nef and RT, respectively, was the optimum concentration 
because it resulted in good detection levels with low background (Figure 4.3C, lane 
8). Detection with positive HIV serum control (LAV Blot 1, Bio-Rad, USA) resulted 
in development of bands of varying intensity with RT giving the highest intensity 
and Tat being the lowest intensity, indicating weak responses to Tat antigen. In 
addition, there was low level of background on the blot which was eliminated by 
increasing the incubation time with Salmonella lysates from 2 hrs to overnight at 4°C 
(data not shown). Subsequently, all incubation of sera with Salmonella lysates was 














Figure 4:1 Coomassie stained SDS-PAGE and Western blot assay for the establishment 
of the optimum amount of proteins for cocktail preparation. Purified Tat, Nef and RT 
proteins were prepared in four 2-fold serial dilutions showed on top of each SDS-PAGE or 
blot and loaded onto 12.5% electrophoresis gel. The proteins were bound to the membrane 
and detected with anti-Histag antibody. Figures shows Coomassie-stained SDS-PAGE gels 
of Tat, Nef and RT proteins after migration (A-C), Coomassie-stained SDS-PAGE gels after 
transfer of the proteins to the membrane (D-F) and Western blot assays with anti-Histag 
antibody detection (G-I). Numbers on the top of the SDS-PAGE gels or Western blots 
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Figure 4: 2 Western blot assay for the establishment of optimum amount of proteins in 
a cocktail form. Purified Tat, Nef and RT proteins were prepared in cocktails containing 2-
fold serial dilutions and loaded onto 12.5% electrophoresis gel. The proteins were bound to 
the membrane and detected with anti-Histag antibody. Lane 1: Multicolour broad range 
protein ladder, Lane 2: Cocktail 1: containing 0.022 µg Tat, 0.035 µg Nef & 0.06 µg RT, 
Lane 3: Cocktail 2: containing 0.011 µg Tat, 0.018 µg Nef & 0.03 µg RT, Lane 4: Cocktail 
3: containing 0.006 µg Tat, 0.009 µg Nef & 0.015 µg RT, Lane 5: Cocktail 4: containing 
0.003 µg Tat, 0.0045 µg Nef & 0.0075 µg RT, Lane 6: Cocktail 5: containing 0.002 µg Tat, 
0.00023 µg Nef & 0.004 µg RT, Lane 7: Cocktail 6: containing 0.001 µg Tat, 0.001 µg Nef 
& 0.002 µg RT, Lane 8: Cocktail 7: containing 0.0005 µg Tat, 0.0005 µg Nef & 0.001 µg 
RT, Lane 9: Cocktail 8: containing 0.011 µg Tat, 0.00025 µg Nef & 0.0005 µg RT, Lane 
10: Cocktail 9: containing 0.00025 µg Tat, 0.00013 µg Nef & 0.0003 µg RT.  
 
 
Figure 4: 3 Western blot assay for establishment of the optimum dilution of secondary 
antibody. Purified Tat, Nef and RT antigens were diluted to 2-fold concentrations in a 
cocktail and loaded onto 12.5% electrophoresis gel. The proteins were bound to the 
membrane that was cut into strips. The strips were incubated with positive HIV control 
sample and detected with 2-fold serial dilutions of anti-human secondary antibody. Lane 1: 
Multicolour broad range protein ladder, Lanes 2, 4, 6, 8 & 10: Cocktail 1 contained 0.022 
µg Tat, 0.035 µg Nef & 0.06 µg RT, Lanes 3, 5, 7, 9 & 11: Cocktail 2 contained 0.011 µg 
Tat, 0.018 µg Nef & 0.03 µg RT. Numbers on the top of the Western blot represent dilution 
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4.6.2 Detection of HIV-1 Tat, Nef and RT antibodies in human sera by 
Western blot assay 
Purified recombinant Tat, Nef and RT proteins were used as antigens to detect the 
prevalence of antibodies against these proteins in 481 serum samples from HIV-1 
infected individuals. Each serum from HIV-1 positive showed an individual response 
pattern, reacting with one, two or all three recombinant proteins on the strips at 
different levels of intensity. A representative Western blot assay is depicted in Figure 
4.4.  
The prevalence of antibodies to recombinant Tat, Nef and RT antigens in the sera 
from individuals with various CD4 counts and viral loads are shown in Table 4.1. 
The prevalence of antibodies to the antigens was classified into eight various 
categories and is summarized in Table 4.1. Antibodies to all three antigens (Tat, Nef 
and RT) were detected in 29 (6%) of 481 sera samples from HIV-1 infected 
individuals with various CD4 counts. None of the serum samples had positive 
responses to both Tat and Nef antigens in the absence of anti-RT responses. 
Similarly, none of the samples tested positive for Nef alone or Tat alone in the 
absence of anti-RT responses. Antibodies to Nef and RT antigens but not to Tat were 
detected in 191 (40%) of 481 HIV positive sera samples. A prevalence of 2% was 
detected for anti-Tat and anti-RT antibodies but not anti-Nef antibodies. Two 
hundred and ten of 481 HIV positive sera samples had anti-RT antibodies but not 
anti-Nef and anti-Tat antibodies. Thirty seven (8%) of 481 sera samples were 
negative for all three antigens. Thus, an overall of 444 of 481 sera samples from 
HIV-infected individuals tested positive for HIV antibodies, indicating a sensitivity 
of 92% for the Western blot assay (calculated as shown in section 4.2.3). At the same 
time, 20 of 20 HIV negative sera from healthy individuals tested negative for HIV 















Figure 4.4: Representative Western blot assay showing the antibody responses to 
recombinant Tat, Nef and RT antigens in the sera of HIV-1 infected individuals. A 
cocktail containing equal molar concentration of Tat, Nef and RT antigens was migrated 
onto 12.5% SDS-PAGE and the antigens were electroblotted to the membrane. The 
membrane was cut into strips and used to screen the presence of HIV-1 antibodies with sera 
from HIV-1infected individuals. Each strip indicates the antibody responses to recombinant 
Tat, Nef and RT antigens. Strip labelled His-tag was bound with a cocktail containing Tat, 
Nef and RT antigens which were detected with anti-Histag antibody. A –HIV labelled strip 
was bound with a cocktail containing Tat, Nef and RT antigens which were detected with 
HIV negative serum and served as negative control.  
 
Table 4.1: Frequency of anti-HIV-1 antibodies in the serum samples from HIV-1 infected 
individuals 
     Presence of positive antibodies (%) to:  
Tat protein:  +           +          -           +         +         -           -              - 
Nef protein:  +           +          +           -          -         +          -              -                                               
RT protein:   +           -          +           +          -         -          +              -                                            
                      
 
CD4 Category (cells no/µl)        n           
    
Group A: CD4 500 or more    115         7(6)    0(0)    33(29)     2(2)     0(0)     0(0)     67(58)     6(5)       
Group B: CD4 201 to 499       286          19(7)   0(0)   128(45)    5(2)    0(0)     6(2)    101(35)   27(9)       
Group C: CD4 200 or less       80           3(4)     0(0)    30(38)     1(1)    0(0)     0(0)     42(53)     4(5)       
 
Total:                                         481         29(6)   0(0)   191(40)    8(2)    0(0)     6(1)   210(44)    37(8)       
 
Viral Load Category  
(RNA copies/ml) 
 
1.VL 50 to 500                           20           1(5)    0(0)      5(25)     1(5)      0(0)     1(1)     11(55)    1(5) 
2. VL 501 to 5000                      56           1(2)    8(14)   16(29)     2(4)     1(2)     0(0)     24(43)    4(7) 
3. VL 5001 to 20, 000                77           6(8)    0(0)     35(45)    0(0)      0(0)     2(3)     29(38)    5(6) 
4. VL 20001 or  more              129         11(9)   0(0)     47(36)    0(0)      0(0)     0(0)     64(50)    7(5) 
 
Total:                                        282          19(7)   8(3)    103(37)    3(1)    1(0.4)   3(1)  128(45)   17(6) 
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4.6.2 Statistical analysis 
The Western blot analysis indicated that 7% of 115 of serum samples in group A 
(CD4: 500 cells/µl or more), 8.4% of 286 of the serum samples in group B (CD4: 
201 to 499 cells/µl) and 5% of 80 serum samples in group C (CD4: 200 cells/µl or 
less) had anti-Tat antibodies (Table 4.2). A two-tailed Fisher‟s exact test showed that 
the frequency of the positive responses between groups A & B, groups B & C and 
groups A & C were not significantly different (Table 4.2; p= 0.689, p= 0.474 and p= 
0.764). The analyses showed that all the p-values between various viral loads were 
also found to be far greater than 0.05, indicating that there were no significant 
differences between the groups (Table 4.2). An overall amount of 7.5% of the serum 
samples from HIV-1 infected individuals had anti-Tat antibodies. The frequency of 
antibody responses seemed to decrease in individuals having less CD4 count and 
higher viral load (Table 4.2).  
The prevalence of antibody responses showed that 39 of 115 serum samples (33.9%) 
in group A, 156 of 286 (54.5%) serum samples in group B and 33 of 80 (41.3%) 
serum samples from HIV-1 infected individuals in group C reacted with recombinant 
Nef antigen (Table 4.3). The prevalence of anti-Nef antibodies in group B (CD4: 201 
to 499 cells/µl) is significantly higher than the prevalence in groups A and C. 
However, the frequency of anti-Nef antibodies was not significantly different 
between groups A and C (Fishers‟ exact test, p= 0.366). Also the prevalence of anti-
Nef antibodies between various levels of viral load was not significantly different 
(Table 4.3).  In overall 47.4% of the serum samples from HIV-1 infected individuals 
had anti-Nef antibodies. Serum samples from group B (CD4: 201 to 499 cells/µl) and 
group 3 (VL: 501 to 20 000 RNA copies/ml) had the highest prevalence of anti-Nef 
antibody (Table 4.3). 
 
Further analysis indicated that 106 of 115 (92.2%) serum samples in group A, 257 of 
286 (89.9%) serum samples in group B and 76 of 80 (95%) serum samples in group 
C had anti-RT antibodies (Table 4.4). The prevalence of antibodies against RT 
antigen was not significantly different between groups A, B and C (Table 4.4). The 
frequency of anti-RT antibodies in groups with various levels of viral load was 
significantly different between only groups 3 & 4 and 2 & 4 (Table 4.4; Fishers‟ 
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anti-RT antibodies is significantly higher in individuals with very high viraemia (VL: 
20001 RNA copies/ml or more) than those with moderate viraemia (VL: 5001 to 
20000 RNA copies/ml).  Overall, 91.3% of HIV positive individuals had anti-RT 
antibodies.  
 
Additional analysis looked at the prevalence of antibodies to recombinant Tat, Nef 
and RT antigens in the serum samples of HIV-infected heterosexual partners. As 
shown in Table 4.5, the frequency of anti-Tat antibodies between the sera samples 
from heterosexual partners was 8.9% and 9.7% for male and female individuals, 
respectively. The prevalence of anti-Nef antibody was 44.3% and 43.6% for female 
and male individuals, respectively, while those for anti-RT antibodies were 91% and 
96% (Table 4.5). There were no significant differences in the frequency of antibodies 
between male and female heterosexual partners (Fishers‟ exact test: p= 0.829; p= 
1.000; p= 0.195 for anti-Tat, anti-Nef and anti-RT, respectively).  
 
Table 4.2: Anti-Tat antibody frequency in the sera of HIV-1 infected individuals with 
various levels of CD4 and viral load. 
CD4 Categories  (cells no/µl)               n Tat positive 
response in (%) 
Tat negative 
response in (%) 
p values by Fisher’s 
exact test 
Group A: CD4 500 or  more 115 8 (7) 107 (93) A vs B: p = 0.689 
Group B: CD4 201 to 499 286 24 (8.4) 262 (91.6) B vs C: p  = 0.473 
Group C: CD4 200 or less 80 4 (5) 76 (95) A vs C: p  = 0.765 
     
Total 481 36 (7.5) 445 (92.5)  
     
Viral load (RNA copies/ml)     
     
1. VL 50 to 500 20 2(10) 18 (90) 1 vs 2 = 0.602 
2. VL 501 to 5000 56 3(5.4) 53(94.6) 2 vs 3 = 0.239 
3. VL 5001 to 20 000 77 9(11.6) 68(88.4) 3 vs 4 = 0.474 
4. VL 20001 or  more 129 11(8.5) 118(91.5) 1 vs 3 = 1.000 
    1 vs 4 =0.687 
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Table 4.3: Anti-Nef antibody frequency in the sera of HIV-1 infected individuals with 
various levels of CD4 and viral load. 
CD4 Categories  (cells no/µl)               n Nef positive 
response in (%) 
Nef negative 
response in (%) 
p values by Fisher’s 
exact test 
Group A: CD4 500 or more 115 39  (33.9) 76  (66.1) A versus  B =0.0002 
Group B: CD4 201 to 499 286 156 (54.5) 130 (45.5) B versus  C =0.043 
Group C: CD4 200 or less 80 33 (41.3) 47 (58.7) A versus  C =0.366 
     
Total 481 228 (47.4) 253 (52.6)  
     
Viral load (RNA copies/ml)     
     
1. VL 50 to 500 20 7(35) 13(65) 1 vs 2 = 0.438 
2. VL 501 to 5000 56 26(46.4) 30(53.6) 2 vs 3 = 0.867 
3. VL 5001 to 20 000 77 44(57.1) 33(42.9) 3 vs 4 = 0.066 
4. VL 20001 or more 129 58(45) 71(55) 1 vs 3 = 0.621 
    1 vs 4 = 0.084 
                 Total 282 135(47.9) 147(52.1) 2 vs 4 = 0.183 
 
 
Table 4.4: Anti-RT antibody frequency in the sera of HIV-1 infected individuals with 
various levels of CD4 and viral load. 
CD4 Categories  (cells no/µl)               n RT positive 
response in (%) 
RT negative 
response in (%) 
p values by Fisher’s 
exact test 
Group A: CD4 500 or more 115 106 (92.2) 9 (7.8) A vs B =0.574 
Group B: CD4 201 to 499 286 257 (89.9) 29 (10.1) B vs C =0.189 
Group C: CD4 200 or less 80 76 (95) 4(5) A vs C =0.565 
     
Total 481 439(91.3) 42(9)  
     
Viral load (RNA copies/ml)     
     
1. VL 50 to 500 20 18 (90) 2 (10) 1 vs 2 = 1.000 
2. VL 501 to 5000 56 51 (91.1) 5 (8.9) 2 vs 3 = 1.000 
3. VL 5001 to 20 000 77 69 (89.6) 8 (9.4) 3 vs 4 = 0.0001 
4. VL 20001 or more 129 85(65.9) 44(34.1) 1 vs 3 = 1.000 
    1 vs 4 = 0.036 
                 Total 282 223 (79.1) 59(20.9) 
 
2 vs 4 = 0.0002 
 
 
Table 4.5: Comparison of the prevalence of antibodies to HIV-1 Tat, Nef and RT antigens in 
the sera of HIV-1 infected heterosexual partners. 
Antibodies to: Gender n Positive response Negative response p-values (Fishers’ 
exact test) 
Tat F 124 11 (8.9) 113 (91.1) F vs M = 0.829 
 M 124 12 (9.7) 112 (90.3)  
Total  248 23 (9.3) 225 (90.7)  
 
     
Nef F 124 55 (44.3) 69 (55.7) F vs M = 1.000 
 M 124 54 (43.6) 70 (56,4)  
Total  248 109 (43.9) 139(56.0)  
 
     
RT F 124 113 (91) 11 (9) F vs M = 0.195 
 M 124 119 (96) 5 (4)  
Total  248 232 (94) 16 (7)  
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4.6.1  DISCUSSION 
It is well known that most antibodies against structural proteins (Gag, Pol (RT) and 
Env) are more readily detected in higher frequencies than those targeting regulatory 
(Tat and Rev) and accessory (Nef, Vif, Vpr and Vpu) proteins (Reiss et al., 1990; 
Letvin and Walker, 2003). This may explain the exclusion of regulatory and 
accessory proteins in most current commercial HIV detection kits and diagnostic 
tools. HIV-1 recombinant Tat, Nef and RT proteins play an important role in 
pathogenesis of HIV-1 infection by promoting virus replication (Chang et al., 1994; 
Havlir et al., 1996).                                                                                                                                                                                                                   
 
4.6.2 Optimisation of the Western blot assay 
The Western blot assay was successfully optimized by establishing equal banding 
pattern of Tat, Nef and RT antigens and optimum titration of anti-Human IgG 
alkaline phosphatase conjugate. Molar equivalents of 0.011 µg Tat, 0.018 µg Nef and 
0.03 µg RT (which were the minimal concentration that could still be detected) in 
cocktail preparation was found to be optimum for these Western blot assays, 
indicating that the purification process resulted in production of recombinant proteins 
of high purity. The transfer efficiency of Tat, Nef and RT proteins was determined 
by staining the SDS-PAGE gel with Coomassie blue after transfer of proteins to the 
PVDF membrane. It appeared that the transfer efficiency of Tat antigen was poor 
compared to transfer efficiency of Nef and RT proteins. This may have occurred due 
to the fact that the transfer efficiency can be as low as 10% with semi-dry blotting 
method especially when using hydrophobic proteins such as Tat (Bio-rad semi-dry 
booklet, USA). During optimisation, a lot of background was observed (data not 
shown). However, this problem was solved by incubating the sera with Salmonella 
cell lysates. This process proved to be beneficial in getting rid of the reactive 
antibodies to Salmonella proteins which is a common gut pathogen (Dykhuizen et 
al., 1996). In addition, it did not appear to affect the signal intensity of the bands for 
Tat, Nef and RT antigens. Indeed, overnight pre-incubation of sera with the 
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4.6.2 Detection of HIV-1 antibodies to recombinant Tat, Nef and RT antigens 
by Western blot assay 
The performance of a Western blot assay is an important consideration when 
estimating the effectiveness of the test in detecting the presence of specific 
antibodies or antigens of interest. This may be estimated by calculating the 
specificity and sensitivity of the assay. In this study, sera from HIV-1 uninfected 
individuals were used in parallel with sera from HIV-1 infected individuals to act as 
negative controls as well as for estimating the specificity of the test. All the negative 
control sera were non-reactive in the Western blot assay, indicating specificity 
(proportion of actual negative which are correctly identified) of 100% for the assay. 
The sensitivity (proportion of actual positive which are correctly identified) of this 
Western blot assay was calculated as 92% in detecting the HIV-1 antibodies to Tat, 
Nef or RT antigens. However, this level of sensitivity may be an under-estimate 
because the presence or absence of antibodies to these recombinant proteins could 
not be confirmed using a method of known sensitivity. Also, it is possible to get 
HIV-1 positive sera in which anti-RT, anti-Nef and anti-Tat antibodies are absent or 
below the detection limit of Western blot assay. Thus, it is almost impossible for a 
Western blot based on only these three proteins to achieve a sensitivity of 100%. 
Moreover, considering reactivity to RT alone, which is the only enzymatic protein 
incorporated in the assay, an overall prevalence of 91% was achieved. Therefore, an 
overall sensitivity of 92% and a specificity of 100% were considered to be of a good 
performance for the optimized Western blot assay. However, this assay is still not 
suitable for use as a diagnostic test due to it lower sensitivity as compared ELISA 
HIV test (positive Rapid HIV antibody test). The sensitivity of Rapid HIV antibody 
test is 99.6% and this test was used to diagnose HIV infection in individuals whose 
sera samples were used in the current study.   
 
4.6.2 Statistical analysis of the prevalence of antibodies to recombinant Tat, 
Nef and RT antigens to determine association with viral load or CD4 
counts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Rezza et al., (2005) reported that antibodies against Tat are associated with slow 
progression of AIDS disease in HIV-1 infected individuals. However, antibodies to 
HIV-1 regulatory proteins including Tat are detected at a lower frequency in 
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prevalence of anti-Tat antibodies (detected using Western blot or/and ELISA) in the 
sera of HIV-infected individuals ranged from 16% to 40% (Barone et al., 1986; 
Krone et al., 1988; McPhee et al., 1988). This percentage is relatively higher than 
what is found in the current study (5% to 8.4%). The lower frequency of anti-Tat 
antibodies in this study were similar to those reported previously (Rezza et al., 
2005). The lower frequency of anti-Tat antibodies in current study may be due to 
shuffling of amino acids, which was done to inactivate the Tat protein. Although the 
shuffling of Tat protein preserved the T- cell epitopes and resulted with a robust of 
T-cell responses in vaccinated mice (Burgers et al., 2006), it may have resulted in 
loss of some antigenic sites in the recombinant Tat protein.  Another possible reason 
may be due to a change in the conformational structure of Tat protein by 
denaturation buffer that impeded the Western blot assay to detect the antibodies that 
could have been detected. Statistical analysis showed that there was no significant 
difference in the prevalence of anti-Tat antibodies in the sera from HIV-1 infected 
individuals with different CD4 and viral loads categories. The prevalence of anti-Tat 
antibodies was low in the serum samples of individuals with low viral load (VL: 501 
to 5000 RNA copies/ml).  However, there was no association between the anti-Tat 
antibodies with viral load or CD4 counts. 
 
A 47.4% of sera tested had anti-Nef antibodies and these results were similar to those 
reported previously (Ranki et al., 1987; Allan et al., 1985). However, this percentage 
was relatively lower than some of the other studies reported previously (Wieland et 
al., 1990; Chen et al., 1999; Bahraoui et al., 1990; Reiss et al., 1989). These studies 
reported that 86% (Wieland et al., 1990), 77% (Chen et al., 1999), and 70% 
(Bahraoui et al., 1990) of serum samples from HIV-1 infected individuals had anti-
Nef antibodies. This difference of the prevalence of anti-Nef antibodies in the serum 
samples used in the current study and other related studies is possibly due to 
differences on the HIV-1 subtype in which the Nef protein was derived as well as the 
sensitivity and specificity of its method of detection. The prevalence of anti-Nef 
antibodies was significantly higher in group B than in groups A and C. This may 
have occurred due to high level of immune system activation by high HIV replication 
during this stage in which the immune system is not yet suppressed as a result of 
CD4 cell loss (Albequerque et al., 2007). This increases the production of antibodies 
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anti-Nef antibodies in the sera samples from individuals with high CD4 count and 
low viral load.  However, decreasing levels of the anti-Nef antibody have been 
associated with progression of the disease (Chen et al, 1999). In the current study, 
strong association between the high prevalence of anti-Nef antibodies with a CD4 
count range of CD4: 201 to 499 cells/µl was observed. 
 
RT protein is expressed early in HIV infection and a number of studies have reported 
high quantities of antibodies to recombinant RT protein (Chen et al., 1999; DeVico 
et al., 1988; Laurence et al., 1987; Isaguliants et al., 2000; Jonckheer et al., 2001), 
explaining its potential for usage in kits for HIV-1 diagnosis. In the current study, the 
HIV-1 infected individuals tested had relatively high prevalence of anti-RT 
antibodies regardless of the CD4 count and plasma viral load levels. This showed 
that RT is a good diagnostic protein. The percentage was higher in relative to 
previous study, in which the detection of anti-RT antibodies were detected in the sera 
of HIV-1 subtype B infected individuals (DeVico et al., 1988). This may suggest that 
it is possible that the detection of anti-RT antibodies also depend on the HIV-1 
subtype in which the RT protein was derived. High prevalence of antibodies to RT 
protein is due to the fact that RT is an enzymatic protein and thus it is needed to 
transcribe the viral DNA to RNA during HIV infection (Mitsuya, et al., 1990). Other 
key factors that may be accountable for high prevalence of anti-RT antibodies 
include the fact that RT protein is more immunogenic and it has more antigenic 
epitopes (di Marzo-Veronese et al., 1986; DeVico et al., 1988). 
 
In order to determine whether there was difference in the prevalence of antibodies in 
the sera of HIV-1 infected heterosexual partners, the data was analysed by Fisher‟s 
exact test. There was no significance differences between the prevalence of positive 
responses to these antigens in the serum of heterosexual partners (anti-Tat: p=0.829; 
anti-Nef: p=1.000; anti-RT: p=0.195). These suggest that the presence of antibody 
responses to HIV-1 Tat, Nef and RT antigens were not gender dependent. Despite the 
unavailability of antiretroviral therapy record, some of tested serum samples were 
obtained from individuals that known to have received antiretroviral treatment. This 
may have influenced the prevalence of antibodies making it unrepresentative of 
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In this study, antibodies to recombinant Salmonella enterica serovar Typhimurium 
produced HIV-1 Tat, Nef and RT antigens were detected in the sera of HIV-1 
infected individuals. A prevalence of 7.5%, 47.4% and 91.3% of antibodies to Tat, 
Nef and RT, respectively, were detectable. There was a strong association between 
the high prevalence of anti-Nef antibodies with a CD4 count range of 201 to 499 
cells/µl. However, there were no associations between anti-Tat or anti-RT antibodies 
with any clinical stage. On the basis that antibodies to RT antigen were frequently 
detected in the sera of HIV-infected individuals, it may be valuable to be included in 
diagnostic kits. However, Tat and Nef proteins may not serve a valuable role in HIV 
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Heterologous prime-boost immunization involves the use of two or more different 
vaccines expressing the same or related vaccine immunogens (Donnely et al., 2005; 
Liu, 2003; Schneider et al., 1998). One of the vaccines is used to prime the immune 
system while the other is used subsequently for boosting. Such a combination 
immunization strategy is aimed at induction and enhancement of the immune 
response by avoiding the anti-vector immunity which might be induced by repeated 
booster immunizations with the same vaccine (Donnely et al., 2005; Liu, 2003; 
Schneider et al., 1998). It improves the immune responses better than homologous 
prime boost which involves repeated vaccination with the same vaccine (Schneider et 
al., 1998). The combination of plasmid DNA vaccine with recombinant protein in 
heterologous prime-boost immunization can induce and boost humoral responses as 
well as Th1 and CD8+ cellular responses (Castaldello et al., 2006; Darrah et al., 
2007; Kumer et al., 2006). Humoral responses have been induced with plasmid DNA 
vaccine boosted with the recombinant protein vaccine for HIV-1 (Barnett et al., 
1997; Fuller et al., 1997). Increased level of binding and neutralizing antibodies 
against HIV-1 gp120 was achieved in mice and guinea pigs vaccinated with DNA 
vaccine encoding the gp120 gene (Barnett et al., 1997). The level of antibody 
responses was increased by boosting with recombinant gp120 protein subunit 
(Barnett et al., 1997). St ong gp120-specific IgG titers was also observed in rhesus 
macaques vaccinated with DNA vaccine encoding HIV-1 gp120 and p24 genes and 
boosted with recombinant gp120 and p24 subunit vaccines (Fuller et al., 1997). 
 
A DNA vaccine can also be combined with MVA or other viral vectors for induction 
and enhancement of CD4+ and CD8+ T cell responses. The DNA prime with viral 
vector boost induces high levels of cell-mediated responses far better than when only 
one vaccination is used (Wu et al., 2005). This occurs because it facilitates the 
recognition of additional epitopes of T-cell responses (Wu et al., 2005). High levels 
of CD8+ T cells were induced in mice and monkey models vaccinated with DNA 
and boosted with MVA as compared to either DNA or MVA alone (Robinson et al., 
2006). There was a reduction of severity of SIV infection in macaques vaccinated 
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vaccination regimen resulted in preservation of CD4+ T-cell populations (Mattapallil 
et al., 2006). A DNA vaccine expressing HIV-1 env and gag-protease genes derived 
from HIV-1 subtype C in a prime-boost combination with recombinant MVA has 
been reported to induce high levels of immune responses in vaccinated mice (Kumar 
et al., 2006).  
Burgers et al., (2006 & 2008) from the University of Cape Town‟s HIV Vaccine 
Research group have developed a DNA and MVA vaccines expressing HIV-1 
subtype C multigene polyprotein (Gag, RT, Tat and Nef) and Env gp150. The genes 
were derived from HIV-1 subtype C strains Du422 and Du151 and the two vaccines 
were designated SAAVI DNA-C/C2 and SAAVI MVA-C respectively. SAAVI 
DNA-C comprised of pTHr.grttnC and pTHr.gp150CT plasmids. The pTHr.grttnC 
expresses HIV-1 subtype C gag, rt, tat, nef genes whereas pTHr.gp150CT expressed 
a truncated gp150 (Burgers et al., 2006). SAAVI DNA-C2 comprised of 
pVRCgrttnC and pVCRgp150CT plasmids and expressed the same genes as SAAVI 
DNA-C. The only difference is that the genes were cloned in different vector 
(pVCR) (Burgers et al., 2006). Burgers et al. (2006) showed that vaccination of mice 
with SAAVI DNA-C resulted in generation of robust IFN (interferon)-γ-producing 
CD8+ T cells in response to stimulation with RT peptides. In SAAVI MVA-C, the 
polyprotein, grttn, and the truncated gp150 are inserted into two different sites to 
produce a double recombinant MVA (Burgers et al, 2008). These vaccines have been 
reported to be highly immunogenic when given in DNA prime-MVA boost 
combination and shown to generate high frequencies of HIV-specific CD4+ and 
CD8+ cells in small laboratory animal models (mice and guinea pigs) and baboons 
(Burgers et al., 2008 & 2009; Shephard et al., 2008). Similar results were obtained in 
rhesus macaques vaccinated with same vaccines (unpublished data).  
 
4.6.1 OBJECTIVE 
As previously reported, binding antibodies to HIV-1 subtype C gp120 were 
detectable in the sera of guinea pigs and baboons primed with SAAVI DNA-C/C2 
and boosted with SAAVI MVA-C vaccines (Burgers et al., 2009; Shephard et al., 
2008).  The current study was aimed at evaluating humoral responses induced in 
rhesus macaques by the same vaccines. Thus, the objective of this study is to 
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antigens in the sera of macaques vaccinated with SAAVI DNA-C and SAAVI MVA- 
C by Western blot assay. 
4.6.1 MATERIALS  
Eleven serum samples from rhesus macaques vaccinated with SAAVI-DNA-C/C2 
and SAAVI-MVA-C expressing HIV-1 subtype C polyprotein containing Gag, RT 
Tat, Nef (Grttn) and Env antigens were provided by Dr Wendy Burgers (Division of 
Medical Virology, UCT). The vaccination schedule for the macaques with the DNA 
and MVA vaccines is shown in Table 5.1. 
 
Table 5.1: The vaccination schedule for macaque vaccination with SAAVI DNA-




















1. P18C   Weeks 0, 4 & 8 weeks 16 & 20 Week 7 
2. P23C   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
3. P24C   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
4. P27C   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
5. P37C   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
6. P41C   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
7. P45C   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
8. P67C   Weeks 0, 4 & 8 weeks 16 & 20 Week 7 
9. P3C2   Weeks 0, 4 & 8 weeks 16 & 20 Week 7 
10. P28C2   Weeks 0, 4 & 8 weeks 16 & 20 Week 3 
11. P30C2   Weeks 0, 4 & 8 weeks 16 & 20 Week 7 
*SAAVI DNA C and SAAVI DNA C2 express the same genes (gag, rt, tat, nef and 
gp150) but the only difference is that the genes were cloned in different vectors. 
 
4.6.1 METHODS 
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To establish the optimum dilution of secondary antibody for detection of vaccine-
induced HIV-1 antibodies in the macaque sera, a cocktail containing Tat (0.011 µg), 
Nef (0.018 µg), and RT (0.03 µg) proteins were subjected to 12.5% SDS-PAGE as 
previously described (Chapter 2, section 2.4.11). The proteins were electroblotted 
onto a PVDF membrane (Amersham, UK) as described previously (Chapter 2, 
section 2.4.13). The macaque serum was incubated with Salmonella cell lysates 
overnight at 4°C to remove antibodies to Salmonella cell extracts. The PVDF 
membrane was cut into strips and incubated with macaque sera at a dilution of 1:100 
for 2 hrs on a shaker at room temperature. Anti-monkey IgG secondary antibody 
conjugated to alkaline phosphatase (Sigma, Germany) was diluted in various dilution 
(1: 2000; 1: 4000; 1: 6000; 1: 8000 and 1: 10,000). The strips were washed four 
times (10 min each) with washing buffer (Appendix A: 30) to remove unbound 
antibodies and incubated at serial dilutions of anti-monkey IgG secondary antibody 
conjugated to alkaline phosphatase (Sigma, Germany) for 60 min. The strips were 
washed 4 times at room temperature and the detection was done by developing with 
NBT-BCIP substrate solution for 15 min. After the reaction was stopped by rinsing 
with water, the strips were dried with paper towel and scanned (CanonScan 8000F, 
China). 
 
4.6.2 Detection of the HIV-1 antibodies in macaque sera by Western blot assay 
A cocktail of recombinant Tat (0.011 µg), Nef (0.018 µg) and RT (0.03 µg) proteins 
used for Western blotting experiments was subjected to 12.5% SDS-PAGE at 80 V 
for 2 hrs as described previously (Chapter 2, section 2.4.11). The proteins were 
electrophoretically transferred on to PVDF membranes as previously described 
(Chapter, sections 2.4.13). The membranes were blocked with 5% blocking buffer 
(Appendix A: 30) for 2 hrs at room temperature and left at -4⁰C on an overnight 
shaker. The membranes were dried and kept at 4⁰C until use. The night before the 
detection, the macaques sera (both before vaccination and after vaccination with 
DNA and MVA) were incubated with Salmonella cell lysates at dilution of 1:100 
overnight at 4⁰C to remove the antibodies to Salmonella enterica serovar 
Typhimurium. The membranes were taken out of the fridge, cut into thin strips, 
labelled and soaked in methanol (for 2 min) and water for 5 min. After soaking, the 
strips were washed once for 10 min with washing buffer (Appendix A: 31) and each 
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The sera from macaques before DNA vaccination were used as negative controls. 
The binding of macaque antibodies was detected by goat anti-monkey IgG 
conjugated to alkaline phosphatase (Sigma, Germany) at a dilution of 1:8000 for 60 
min. The strips were washed 4 times with washing buffer (Appendix A: 30) and 
visualized with NBT-BCIP substrate reaction following the manufacturer‟s 
instructions (Roche Diagnostics, Germany). The strips were left in NBT-BCIP 
substrate reaction for 15 min, rinsed with water and dried with paper towel. The 
strips were taped on a white, A4 paper and scanned (CanonScan 8000F, China). 
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4.6.1  RESULTS 
4.6.2 Establishment of the best anti-Monkey IgG titration for detection of 
antibodies in macaque sera 
The concentration of secondary antibody to detect the macaque sera was established 
by comparing the intensity of the reactive bands with serial dilutions at 1:2000. 
1:4000, 1: 6000, 1:8000 and 1:10 000. The results confirmed that concentration of 
secondary antibody at 1:8000 and 1:10 000 dilution showed best detection with no 
background (Figure 4.1, strip 9 & 11). However, only antibodies to recombinant RT 
protein were detected but not to recombinant Nef and Tat proteins (Figure 5.1, strips 
2, 4, 6, 8, & 10). Expectedly, there were no antibody reaction observed in strips 
incubated with sera from macaques before vaccination and served as negative 
controls (Figure 5.1, strips 3, 5, 7, 9 & 11). This indicated that there were no 
antibody responses to Nef and Tat protein in tested macaque sample. 
 
 
Figure 5.1: Titration of secondary antibody (anti-monkey IgG) for detection of 
the macaque sera. A cocktail containing Tat, Nef and RT antigens were separated 
on 12.5% electrophoresis gel, transferred to the membrane that was cut into strips. 
The antigens were reacted with sera from macaques vaccinated with DNA and MVA 
vaccines and sera from macaques before vaccination was used as a negative control. 
The Tat, Nef and RT antigens were visualized with various titrations of anti-monkey 
IgG secondary antibody linked with alkaline phosphatase and NBT/BCIP substrate. 
Strips 1: Multicolour broad range protein ladder. Strips 2, 4, 6, 8 & 10: Strips bound 
with cocktail contained Tat, Nef and RT antigens which were detected with sera of 
macaques vaccinated with DNA and boosted with MVA expressing HIV-1 subtype C 
Grttn & env. (No bands were observed for Nef and Tat antigens because there were 
no detectable antibody responses to these antigens for this particular sample). Strips 
3, 5, 7, 9 & 11: Strips bound with cocktail contained Tat, Nef and RT antigens which 
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4.6.2 Detection of HIV-1 Tat, Nef and RT antibodies in macaque sera  
The prevalence of HIV-1 antibodies against recombinant Tat, Nef and RT antigens 
were investigated in the sera of vaccinated macaques with SAAVI-DNA-C/C2 
vaccine and SAAVI-MVA-C expressing HIV-1 subtype C Gag, RT, Tat, Nef and 
Env proteins. Out of 11 serum samples from macaques vaccinated with DNA vaccine 
and boosted with MVA, only 4 (36%) had anti-Tat antibodies (Figure 5.2, strips 2, 6, 
8 and 14).  Three of 11 (27%) macaque sera had antibodies against recombinant Nef 
antigen (Figure 5.2, strips 2, 6, and 14). However, anti-Nef antibody responses in two 
of these sera were very weak and resulted in the development of very faint bands on 
the blot for Nef antigen (Figure 5.2, strips 2, and 6). Despite of low intensity, 5 
(40%) sera of macaques had anti-RT antibodies. Three of the positive macaque sera 
were obtained at week 3 post the second SAAVI MVA-C vaccination (Figure 5.2, 
strips 2, 6 & 8) and 1 was obtained at week 7 post the second SAAVI MVA-C 
vaccination (Figure 5.2, strips 14). Three bands on Figure 4.2 (strip 24) indicate 
recombinant Tat, Nef and RT antigens which was detected with penta anti-His 
antibody and served as positive control. No antibody responses were detectable in the 
pre-immunization sera of the macaques, suggesting a high specificity for the assay. A 
few serum samples showed some background that may have resulted from non-
specific reactivity. 
 
Figure 5.2: Western blot assay showing the prevalence of HIV-1 (Tat, Nef and 
RT) antibodies in sera of macaques vaccinated with SAAVI-DNA and SAAVI-
MVA. A cocktail containing Tat, Nef and RT antigens were separated on 12.5% 
electrophoresis gel, transferred to the membrane that was cut into strips. The antigens 
were reacted with sera of macaques vaccinated with DNA vaccine and boosted with 
MVA vaccines and sera of macaques before vaccination and used as a negative 
control. The Tat, Nef and RT antigens were visualized with anti-monkey IgG 
secondary antibody linked with alkaline phosphatase and NBT/BCIP substrate. Each  
strip indicates antibody response to HIV-1 Tat, Nef and RT antigen. Black coloured 
strips 2, 4, 6, 8 10, 12, 14, 16, 18, 20, 22: Strips bound with cocktail contained Tat, 
Nef and RT antigens and detected with sera of macaques vaccinated with DNA and 
boosted with MVA expressing HIV-1 subtype C Grttn & env. Red coloured strips 
3, 5, 7, 9, 11, 13, 15, 17, 19, 21 & 23: Strips bound with cocktail contained Tat, Nef 
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and MVA. Strips 24: Positive control strip bound with cocktail contained Tat, Nef 
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4.6.1 DISCUSSION 
Development of HIV-1 vaccine that could induce both humoral and cell mediated 
responses still remains a great challenge. Combination of DNA and MVA based 
vaccines are important for inducing the T cell (CD8+ and CD4+) and humoral 
responses against various pathogens such as HIV (Liu, 2005). Previous studies 
showed that a DNA prime with an MVA boost induces higher magnitudes of both 
humoral and cell mediated responses than either vaccine alone (Kent et al., 1998; 
Schneider et al., 1998). Abundant and high quality CD4+ and CD8+ T- cell 
responses were induced by a prime-boost combination of DNA and MVA vaccines 
in mice, non-human primates and human (Burgers et al., 2008 & 2009; Cosma et al., 
2003; Hirsch et al., 1996; Shephard et al., 2008; Sutter et al., 1994). In the current 
study, the presence of antibodies against recombinant Tat, Nef and RT antigens were 
investigated in the sera of macaques vaccinated with DNA and MVA vaccines 
expressing Gag, Tat, RT, Nef and Env antigens in a prime-boost immunization 
strategy.   
 
4.6.2 Detection of antibodies to Tat, Nef and RT antigens in sera of macaque 
vaccinated with SAAVI DNA-C/C2 and boosted with SAAVI MVA-C  
The results obtained by Western immunoblot assay revealed only 36%, 27% and 
40% of the vaccinated macaques generated detectable antibodies against HIV-1 
recombinant Tat, Nef and RT antigens, respectively. Some of the bands for the 
reactivity of one or more antigens (Tat, Nef and RT) were very faint, suggesting 
presence of low level of antibodies in the tested sera. This was despite the finding 
that high frequencies of T-cell responses to all the five vaccine imunogens, including 
Tat, Nef, and RT, were generated in the peripheral blood of the vaccinated animals 
(Burgers et al, unpublished). The prevalence of antibody responses to Tat, Nef and 
RT antigens in the sera of macaques is lower relative to the prevalence of antibody 
responses in the sera of HIV-1 infected individuals. A possible explanation is that the 
immune system of HIV-1 infected people is continuously exposed to viral antigens, 
thus resulting to high level of detectable anti- Tat, -Nef and -RT antibodies. In 
contrast, macaques were exposed to HIV-1 antigens expressed by the DNA and 
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There are other factors which may have affected weak or absence of binding 
antibody responses to HIV-1 subtype C Tat, Nef and RT antigens in the sera of 
macaques vaccinated with SAAVI DNA-C/C2 and SAAVI MVA-C vaccines. One 
possible explanation is that although MVA-vector vaccines are excellent in boosting 
T-cell responses to heterologous antigens, they are very poor in inducing or boosting 
humoral responses to the same antigens (Mwau et al., 2004). This explained the low 
or absence of binding antibodies in the sera of vaccinated macaques in the current 
study. This, combined with the fact that DNA vaccines themselves are weak inducers 
of humoral responses, may have resulted in undetectable levels of antibodies being 
generated, leading to low prevalence of Tat, Nef and RT antibodies. DNA vaccine 
boosted with protein based vaccine is an effective way of inducing strong binding 
antibody responses against the HIV-1 viral proteins (Richmond et al, 1998). They 
produce a better quality of humoral responses because they produce properly folded  
and glycosylated proteins (Wang et al., 1993). They can also recognise more 
antigenic epitopes as compared to viral vector vaccines (Wang et al., 2005). Previous 
studies demonstrated a high magnitude of antibody responses in mice, rabbits and 
rhesus macaques vaccinated with DNA boosted with protein subunit vaccines 
(Barnett et al., 1997; Doria-Rose et al., 2005; Fuller et al., 1997).  
 
In conclusion, this study showed a low prevalence of antibody responses to HIV-1 
subtype C Tat, Nef and RT antigens in the sera of macaques vaccinated with SAAVI 
DNA-C/C2 and SAAVI MVA-C vaccines. The sera was tested at a dilution of 1/100 
and it is possible that more positive sera  may have been detected at lower serum 
dilution. In addition, this study demonstrated that a Western blot assay based on 
purified HIV-1 Tat, Nef and RT proteins is a useful research tool in detection of 
binding antibodies to corresponding vaccine immunogens in macaque sera. Thus, 
future work to measure the performance of this Western blot test and validation for 






















The aim of the study was to develop a recombinant Salmonella enterica serovar 
Typhimurium expressing HIV-1 subtype C Tat, Nef and RT proteins. The 
recombinant HIV-1 subtype C Tat, Nef and RT were purified and used in Western 
blot assay to detect antibodies to the proteins in the sera of HIV-1 subtype C infected 
individuals from Cape Town, South Africa and macaques vaccinated with candidate 
HIV-1 vaccines, SAAVI-DNA-C/C2 and SAAVI-MVA-C. The following five 
general conclusions were drawn from the study: 
 
 
6.1 Recombinant HIV-1 Tat, Nef and RT proteins were produced from 
Salmonella enterica serovar Typhimurium. 
Recombinant Salmonella containing pGEM+Tat, pGEM+Nef and pGEM+RT 
plasmids expressed high levels of HIV-1 Tat, Nef and RT respectively. Codon 
optimization of the genes, fusion of the genes to the LacZa and use of the lac 
promoter were among the factors that facilitated the high production of the antigens 
by the bacteria.  
 
6.2 Recombinant HIV-1 Tat, Nef and RT proteins were purifed from Salmonella 
enterica serovar Typhimurium. 
HIV-1 Tat, Nef and RT were purified from the recombinant Salmonella enterica 
serovar Typhiumurium. Only Nef, but not Tat and RT could be purified under native 
conditions. This showed that only Nef was expressed as a soluble protein and Tat and 
RT were expressed as inclusion bodies. All the three antigens were purified in bulk 
under denaturing conditions. This suggested that even Nef was expressed mainly as 
inclusion bodies. The His-tag facilitated the purification of the HIV-1 Tat, Nef and 
RT proteins by affinity chromatography. It was concluded that Salmonella was a 
good heterologous bacterial expression system which could be used to produce 
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6.3 Antibodies to HIV-1 Tat, Nef and RT were detected in sera of HIV-1 
infected individuals 
HIV-1 subtype C Tat, Nef and RT antigens purified from recombinant Salmonella 
enterica serovar Typhimurium were capable of detecting HIV-1 anti-Tat, anti-Nef 
and anti-RT antibodies in the sera of HIV-1-infected individuals by Western blot 
method.  Sera from 91% of the HIV-positive individuals reacted with RT, while only 
47.4% and 7.5% of the HIV-postive individuals reacted to Nef and Tat respectively. 
Low prevalence of anti-Tat antibodies may be due to shuffling of Tat amino acids 
that was done to inactivate the Tat protein. Antibodies to all the three proteins was 
detected in 6% of the sera while 42% and 45% of the sera had antibodies to two and 
one (principally to RT) proteins respectively. The levels of antibodies to Tat, Nef and 
RT in the sera of the individuals probably varied as the intensities of the Western blot 
bands were observed to vary. There was a strong association between the high 
prevalence of anti-Nef antibodies with one of the clinical stage (CD4 count of 201 to 
499 cells/µl). However, there were no associations of anti-Tat and anti-RT antibodies 
with CD4 counts or viral load. The observation that antibodies to RT antigen were 
frequently detected in the sera of HIV-infected individuals suggests a possible 
application of purified RT proteins to improve current HIV diagnostic kits. 
 
6.4 Antibodies to HIV-1 Tat, Nef and RT were detected in sera of macaques 
vaccinated with HIV vaccines. 
HIV-1 Tat, Nef and RT antigens purified from the recombinant Salmonella enterica 
serovar Typhimurium were further shown to be reactive to HIV-1 anti-Tat, anti-Nef 
and anti-RT antibodies respectively in sera of macaques previously vaccinated with 
HIV-1 subtype C vaccines expressing Gag, RT, Tat, Nef and Env antigens. The 
purified Tat, Nef and RT reacted with only 36%, 27% and 40% respectively of sera 
of vaccinated animals. This suggested that the macaques did not produce enough 
antibodies against DNA vaccine probably because MVA was poor in boosting the 
antibody responses. However, this study demonstrated that a Western blot assay 
based on purified HIV-1 Tat, Nef and RT proteins is a possible useful research tool 
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6.5 Further studies need to be done in future  
Since the Salmonella enterica serovar Typhimurium developed in this study 
produced high levels of the HIV antigens, further studies are needed to show whether 
the bacteria can be used as a HIV vaccine vector.  It further needs to be investigated 
to check whether the purified proteins can be used as HIV subunit vaccines. The 
purified proteins also need to be investigated on their suitability for use as 
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APPENDIX A 
MEDIA, SOLUTIONS AND REAGENTS 
BACTERIAL AND SOLUTIONS  
1. 2x Yeast Tryptone (2YT) Agar  
Tryptone         16 g 
Yeast extracts         10 g 
NaCl          5 g 
Agar          15 g 
DH2O          1000 ml   
The mixture was autoclaved and upon cooling, the supplements or antibiotics were added 
and poured into plates to solidify. 
 
2. 2x YT media  
Tryptone          16 g 
Yeast extracts         10 g 
NaCl            5 g 
DH2O          900 ml 
The pH was adjusted to 7.0 with NaOH, made up the volume to 1000ml with dH2O and 
autoclaved. 
 
3. 100 mg/ml Ampicillin 
Ampicilin         1 g 
DH2O          10 ml 
The mixture was filter sterilized and stored at -70⁰C in 100ul aliquots.   
 
4. 100 mg/ml IPTG 
IPTG          1 g 
DH2O          10 ml 
The mixture was filter sterilized and stored at -70⁰C in 100ul aliquots.  
 
 
5. 100x Aromix compounds 
4- aminobenzoic acid        200 mg 
2.3-Dihydroxyl benzoic acid       200 mg 
L-phenylalanine        800 mg 
L-tryptophan         800 mg 
DH2O          200 ml 
The mixture was filter sterilized and stored at -70⁰C in 30 ml aliquots.  
 
6. 100x Tyrosine 
L-Tyrosine         800 mg 
0.1M HCL         200 ml 
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BUFFERS FOR PREPARATION OF COMPETENT CELLS 
 
7. 10% Glycerol stock 
Glycerol         10 ml 
DH2O up to          100 ml  
 Autoclaved and stored at 4⁰C. 
 
8. 1 M Calcium chloride  
CaCl. 2H2O         29.4 g 
DH2O up to          200 ml  
 Autoclaved and stored at 4⁰C. 
 
SOLUTIONS AND GEL PREPARATION FOR ELECTROPHORESIS GEL 
 
9. 0.5 M EDTA, pH 8.0 
EDTA          93.1 g 
DH2O to         100 ml  
The pH was adjusted to 8.0 and volume made up to 300 ml and stored at room temperature. 
 
10. 1X Tris-Borate-EDTA (TBE) Buffer 
Tris-HCl          269 g 
Boric acid         137.6 g 
EDTA, pH8.0         18.63g 
DH2O           25L.  
This is usually prepared for the entire lab users in 25 L bottle and stored at room 
temperature. 
 
11. 1.5% agarose gel 
Agarose powder        7.5 g 
DH2O         500 ml  
The mixture was melted on a microwave and ethidium bromide was added to a total 
concentration of 2 µl/ml and stored at 37ºC. 
 
SOLUTIONS FOR ISOLATION OF PLASMID DNA 
 
12. 10X  Solution I stock  (Resuspension solution):  
1 M Tris-HCl pH 8.0         25 ml 
20% Glucose          45.5 ml  
0.5 M EDTA pH 8.0         20 ml 
DH20 up to          100 ml 
The solution was stored at room temperature. 
 
13. Solution II (Lysis solution) 
10 N NaOH          2 ml 
25% SDS (w/v)         10 ml 
DH20           100 ml 
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14 Solution III (Neutralization solution) 
K-acetate         147 g 
DH20          250 ml 
The pH of the solution was adjusted with acetic acid to 4.8 and the volume was made up with 
dH20 up to 500 ml, autoclaved and stored at 4°C. 
 
 
15 70% Ethanol 
Ethanol          70 ml 
DdH20           100 ml 
Stored at room temperature.  
 
16 Tris-EDTA (TE) Buffer pH 9.0 
1 M Tris HCl         2 ml 
1 M EDTA          200 ul 
DH20           150 ml 
The pH of the solution was adjusted to 9.0 and the volume made up to 200 ml. Stored at 
room temperature. 
 
BUFFERS AND GEL PREPARATION FOR SDS-PAGE GEL 
 
17 Acrylamide/bis (30% T, 2.67%C)   
Acrylamide          87.6 g 
 N‟N‟-bis –methylene-acrylamide      2.4 g 
 DH20          300 ml 
Since acrylamide is a neurotoxin, it was weighed out with gloves on and a gas mask. The 
solution was filter sterilized and stored at 4⁰C. 
 
18 1.5M Tris-HCL, pH 8.8 
Tris base          27.33 g   
 DH20          100 ml  
The pH was adjusted 8.8 with 6 N HCL and volume made up to 150 ml with distilled water 
and stored at 4⁰C. 
 
19 0.5 M Tris-HCL, pH 6.8 
Tris base          9 g    
DH20           100 ml  
The pH was adjusted 6.8 with 6N HCL and volume made up to 150ml with distilled water 
and stored at 4⁰C. 
 
20 10% SDS  
SDS           10 g  
DH20           80 ml  
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21 2X Laemmli loading dye (SDS reducing agent)  
Distilled water          3.8 ml 
0.5 M Tris-HCL, pH 6.8       1.0 ml 
Glycerol          0.8 ml 
10% SDS         1.6 ml 
2-mercaptoethanol        0.4 ml 
1% bromophenol blue        0.4 ml 
           8.0 ml 
Stored at 4⁰C.  
 
22 12.5% Resolving gel preparation-0.375 M Tris, pH 8.8  
Distilled water         3.35 ml 
1.5 M Tris-HCL, pH 8.8       2.5 ml 
10% SDS stock         100 ul 
Acrylamide 30%        4.0 ml 
10% Ammonium persulphate (Freshly made)     50 ul 
TEMED         5.0 ul 
          10 ml 
Add all reagents except APS and TEMED and degas under vaccum for 15 min. To initiate 
polymerization add APS and TEMED and swirl gently to mix. 
 
23 4% Stacking gel preparation- 0.126 M Tris, pH 6.8  
Distilled water         6.1 ml 
0.5 M Tris-HCL, pH 6.8       2.5 ml 
10% SDS stock         100 µl 
Acrylamide/bis (30% stock)       1.33 ml 
10% Ammonium persulphate (Freshly made)     50 ul 
TEMED         10 ul 
          10 ml 
Add all reagents except APS and TEMED and degas under vaccum for 15 min. To initiate 
polymerization add APS and TEMED and swirl gently to mix. 
 
24 10X SDS-PAGE Running Buffer 
Tris-HCl                                                                                                       30.3 g 
Glycine                                                                                                        144 g 
SDS                                                                                                                10 g 
DH2O           1000 ml 
The buffer was stored at 4⁰C 
 
25 1X SDS-PAGE Running Buffer 
10X SDS-PAGE Running buffer      100 ml 
DH2O           900 ml 
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BUFFERS FOR PROTEIN EXTRACTION, PURIFICATION AND 
WESTERN BLOT 
 
26 Protein lysis buffer 
10% SDS         60 ml 
50% Glycerol         40 ml 
1 M Tris-base, pH 6.8        12.5 ml 
DH2O to          200 ml 
The buffer was stored at room temperature.  
 
27 1 M Tris-HCL, pH 8.0 
Tris-base         36.3 g 
DH2O           150 ml 
The pH of the buffer was adjusted to 8.0 and volume made up to 200 ml and stored at 
room temperature. 
 
28 2 M Sodium Chloride (Nacl) 
Nacl          58.44 g 
DH2O to          500 ml 
The buffer was stored at room temperature. 
  
29 1 M Tris, ph 7.5 
Tris-base         36.3 g 
DH2O           150 ml 
The pH of the buffer was adjusted to 7.5 and volume made up to 200 ml and stored at 
room temperature. 
 
30 Blocking/Diluent/Washing buffer 
Fat Free Milk         40 g  
1 M Tris pH 7.2        40 ml 
2 M Nacl         150 ml 
Tween 20          5 ml   
DH2O           700 ml 
The mixture was allowed to dissolve and made up to 1L with distilled water. 
 
31 Substrate 
 NBT/BCIP         1pellet 
 DH2O                       10 ml 
The mixture was allowed to dissolve prior use. 
 
32 10X Transfer Buffer 
Tris-HCl                                                                                                       30.3 g 
Glycine                                                                                                        144 g 
DH2O           1000 ml 
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33 1X Transfer Buffer 
10X Transfer buffer        100 ml 
Methanol                                                                                                      200 ml 
DH2O           600 ml 
The pH of the buffer was checked prior use and if necessary the pH was adjusted to 8.3.  
 
34 Coomassie blue staining solution  
Coomassie brilliant blue                                                                       1 tablet 
Methanol                                                                                                    400 ml 
Glacial acetic acid                                                                                        70 ml 
DH2O           530 ml 
The solution was wrapped with foil and stored at 4⁰C. 
 
35 Destaining solution 
Methanol                                                                                                    200 ml 
Glacial acetic acid                                                                        70 ml 
DH2O           730 ml 
The solution was prepared under vacuum and stored at room temperature. 
 
36 1 M NaH2PO4 
NaH2PO4         5.58 g 
DH2O to          200 ml 
The solution was stored at 4°C. 
 
37 1 M Tris-base 
Tris-base         0.25 g 
DH2O to          400 ml 
The solution was stored at 4°C. 
 
38 Denaturing Lysis buffer (buffer B) 
NaH2PO4 (1 M)        20 ml 
Tris-base (1 M)        2 ml 
Urea (8 M)         96.9 g 
DH2O            100 ml 
The urea was dissolved and the pH was adjusted to 8.0 and the volume made up to 200 ml 
with distilled water. This was prepared freshly all the time. 
 
39 Denaturing Wash buffer (buffer C) 
NaH2PO4 (1 M)        20 ml 
Tris-base (1 M)        2 ml 
Urea (8 M)         96.9 g 
DH2O            100 ml 
The urea was dissolved and the pH was adjusted to 6.3 and the volume made up to 200 ml 
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40 Denaturing Elution buffer (buffer E) 
NaH2PO4 (1M)        20 ml 
Tris-base (1M)        2 ml 
Urea (8M)         96.9 g 
DH2O            100 ml 
The urea was dissolved and the pH was adjusted to 4.5 for elution of 10-30 kDa proteins and 
3.7 for 50-100 kDa proteins. The volume made up to 200 ml with distilled water and this was 
prepared freshly all the time. 
 
41 Native Lysis buffer  
NaH2PO4. H2O (50 mM)       6.9 g 
NaCl (300 mM)        17.54 g 
Imidazole (10 mM)        0.68 g 
DH2O            100 ml 
The mixture was dissolved and the pH was adjusted to 8.0 with NaOH and the volume made 
up to 200 ml with distilled water and stored at 4⁰C. 
 
42 Native Wash buffer  
NaH2PO4. H2O (50 mM)       6.9 g 
NaCl (300 mM)        17.54 g 
Imidazole (20 mM)        1.36 g 
DH2O            100 ml 
The mixture was dissolved and the pH was adjusted to 8.0 with NaOH and the volume made 
up to 200 ml with distilled water and stored at 4⁰C. 
 
43 Native Elution buffer 
NaH2PO4. H2O (50 mM)       6.9 g 
NaCl (300 mM)        17.54 g 
Imidazole (250 mM)        17 g 
DH2O            100 ml 
The mixture was dissolved and the pH was adjusted to 8.0 with NaOH and the volume made 
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APPENDIX B 
PLASMID MAP  
 














The pGEM(R)-T Easy Vector has been linearized with EcoRV at base 60 of this 
sequence and a T added to both 3' –ends (adapted from Promega, USA catalogue). This 
vector is designed for cloning PCR products. The pGEM-T Easy vector has a mutated 
version pMB1 origin of replication and this makes the plasmid to have a copy number of 
300-400 per bacterial cell. The pMBI origin of replication is closely related to that of CoIE1. 
The CoIE1 origin of replication makes a plasmid to have a copy number of 300-500 per cell. 
 
 




1         ATGACCATGATTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
1          M  T  M  I  T  P  S  Y  L  G  D  T  I  E  Y  S  S  Y  A  S  
 
61        CATCATCATCATCATCACATCGAAGGTCGTGGCGCCCATATGCTGGGCATTAGCTATGGC 
21         H  H  H  H  H  H  I  E  G  R  G  A  H  M  L  G  I  S  Y  G   
 
121       CGCAAAAAACGTCGTCAGCGTCGTAGCACCCCGCCGAGCAGCGAAGATCATCAGAACCCG 
41         R  K  K  R  R  Q  R  R  S  T  P  P  S  S  E  D  H  Q  N  P   
 
181       ATTAGCAAACAGCCGCTGCCGCAGACCCGTGGCGATCCGACCGGCAGCGAAGAAAGCAAA 
61         I  S  K  Q  P  L  P  Q  T  R  G  D  P  T  G  S  E  E  S  K   
 
241       AAAAAAGTCGAAAGCAAAACCAAAACCGATCCGTTTGATTGCAAATATTGCAGCTATCAC 
81         K  K  V  E  S  K  T  K  T  D  P  F  D  C  K  Y  C  S  Y  H   
 
301       TGCCTGGTGTGCTTTCAGACCAAAGGTCTGGGTATCTCCTACGGTCGTAAAAAGCGCATG 
101        C  L  V  C  F  Q  T  K  G  L  G  I  S  Y  G  R  K  K  R  M   
 
361       GAACCGATTGATCCGAATCTGGAACCGTGGAATCATCCGGGCAGCCAGCCGAATACCCCG 
121        E  P  I  D  P  N  L  E  P  W  N  H  P  G  S  Q  P  N  T  P   
 
421       TGCAACAAATGCTATTGTAAGTACTGTTCCTACCATTGCTTGGTCGACTAA 
141        C  N  K  C  Y  C  K  Y  C  S  Y  H  C  L  V  D  *   
AmpR 
LacZ  (5 ) domain  
LacZ  (3 ) domain  















1         ATGACCATGATTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
1          M  T  M  I  T  P  S  Y  L  G  D  T  I  E  Y  S  S  Y  A  S  
 
61        CATCATCATCATCATCACATCGAAGGTCGTGGCGCCCATATGGTGGGCTGGCCGGCGGTG 
21         H  H  H  H  H  H  I  E  G  R  G  A  H  M  V  G  W  P  A  V   
 
121       CGTGAACGTATTCGTCGTACCGAACCGGCGGCGGAAGGCGTGGGCGCGGCGAGCCAGGAT 
41         R  E  R  I  R  R  T  E  P  A  A  E  G  V  G  A  A  S  Q  D   
 
181       CTGGATAAACATGGCGCGCTGACCAGCAGCAATACCGCGCATAACAATCCGGATTGCGCG 
61         L  D  K  H  G  A  L  T  S  S  N  T  A  H  N  N  P  D  C  A   
 
241       TGGCTGCAAGCGCAGGAAGAAGAACCGGAAGTCGGCTTTCCGGTCCGTCCGCAGGTGCCG 
81         W  L  Q  A  Q  E  E  E  P  E  V  G  F  P  V  R  P  Q  V  P   
 
301       CTGCGTCCGATGACCTATAAAGCGGCGTTTGATCTGAGCTTTTTTCTGAAAGAAAAAGGC 
101        L  R  P  M  T  Y  K  A  A  F  D  L  S  F  F  L  K  E  K  G   
 
361       GGCCTGGAGGGCCTGATCTATAGCAAAAAACGCCAGGATATTCTGGATTTATGGGTCTAT 
121        G  L  E  G  L  I  Y  S  K  K  R  Q  D  I  L  D  L  W  V  Y   
 
421       CATACCCAGGGCTATTTTCCGGATTGGCAGAATTATACCCCGGGTCCGGGCGTGCGTCTG 
141        H  T  Q  G  Y  F  P  D  W  Q  N  Y  T  P  G  P  G  V  R  L   
 
481       CCGCTGACCTTTGGCTGGTGCTTTAAACTGGTGCCGGTCGATCCGGAAGAAGTGGAAGAA 
161        P  L  T  F  G  W  C  F  K  L  V  P  V  D  P  E  E  V  E  E   
 
541       GCGAACAAAGGCGAAAACAACTGTCTGCTGCATCCGCTGAGCCAGCATGGCATGGAAGAT 
181        A  N  K  G  E  N  N  C  L  L  H  P  L  S  Q  H  G  M  E  D   
 
601       GCGGATCGCGAAGTCCTGAAATGGGTCTTTGATAGCAGCCTGGCGCGTCGTCATCTGGCG 
201        A  D  R  E  V  L  K  W  V  F  D  S  S  L  A  R  R  H  L  A   
 
661       CGTGAAAAACATCCGGAATATTATAAAGATGCATAA 





1         ATGACCATGATTACGCCAAGCTATTTAGGTGACACTATAGAATACTCAAGCTATGCATCC 
1          M  T  M  I  T  P  S  Y  L  G  D  T  I  E  Y  S  S  Y  A  S  
 
61        CATCATCATCATCATCACATCGAAGGTCGTGGCGCCCATATGGGGCCCATTAGCCCGATT 
21         H  H  H  H  H  H  I  E  G  R  G  A  H  M  G  P  I  S  P  I   
 
121       GAAACCGTGCCGGTGAAACTGAAACCGGGCATGGATGGCCCGAAAGTCAAACAGTGGCCG 
41         E  T  V  P  V  K  L  K  P  G  M  D  G  P  K  V  K  Q  W  P   
 
181       CTGACCGAAGTGAAAATTAAAGCGCTGACCGCGATTTGCGAAGAAATGGAAAAAGAAGGC 
61         L  T  E  V  K  I  K  A  L  T  A  I  C  E  E  M  E  K  E  G   
 
241       AAAATCACCAAAATCGGCCCGGAAAACCCGTATAACACCCCGATCTTTGCGATCAAAAAA 
81         K  I  T  K  I  G  P  E  N  P  Y  N  T  P  I  F  A  I  K  K   
 
301       GAAGATAGCACCAAATGGCGTAAACTGGTGGATTTTCGCGAACTGAACAAACGCACCCAG 
101        E  D  S  T  K  W  R  K  L  V  D  F  R  E  L  N  K  R  T  Q   
 
361       GATTTTTGGGAAGTCCAACTGGGCATTCCGCATCCGGCGGGCCTGAAGAAAAAGAAAAGC 
121        D  F  W  E  V  Q  L  G  I  P  H  P  A  G  L  K  K  K  K  S   
 
421       GTGACCGTGCTGGATGTCGGCGATGCGTATTTTAGCGTGCCGCTGGATGAAGGCTTTCGC 
141        V  T  V  L  D  V  G  D  A  Y  F  S  V  P  L  D  E  G  F  R   
 
481       AAATATACCGCGTTTACCATCCCGAGCATCAACAATGAAACCCCGGGCATTCGCTATCAG 










Page | 123 
 
541       TATAACGTGCTGCCGCAGGGCTGGAAAGGCAGCCCGGCGATTTTTCAGGCGAGCATGACC 
181        Y  N  V  L  P  Q  G  W  K  G  S  P  A  I  F  Q  A  S  M  T   
 
601       AAAATTCTGGAACCGTTTCGCGCGAAAAACCCGGAAATCGTGATCTATCAGTATATGGCG 
201        K  I  L  E  P  F  R  A  K  N  P  E  I  V  I  Y  Q  Y  M  A   
 
661       GCGCTGTATGTGGGCAGCGATCTGGAAATTGGCCAGCATCGCGCGAAAATTGAAGAACTG 
221        A  L  Y  V  G  S  D  L  E  I  G  Q  H  R  A  K  I  E  E  L   
 
721       CGCGAACATCTGCTGAAATGGGGCTTTACCACCCCGGATAAAAAACACCAGAAAGAACCG 
241        R  E  H  L  L  K  W  G  F  T  T  P  D  K  K  H  Q  K  E  P   
 
781       CCGTTTTTATGGATGGGCTATGAACTGCATCCGGATAAATGGACCGTCCAGCCGATTCAA 
261        P  F  L  W  M  G  Y  E  L  H  P  D  K  W  T  V  Q  P  I  Q   
 
841       CTGCCGGAAAAAGATAGCTGGACCGTCAACGATATTCAGAAACTGGTGGGCAAACTGAAT 
281        L  P  E  K  D  S  W  T  V  N  D  I  Q  K  L  V  G  K  L  N   
 
901       TGGACCAGCCAGATTTATCCGGGCATTAAAGTGCGTCAGTTATGCAAACTGCTGCGTGGC 
301        W  T  S  Q  I  Y  P  G  I  K  V  R  Q  L  C  K  L  L  R  G   
 
961       ACCAAAGCGCTGACGGATATTGTCCCGCTGACGGAAGAAGCGGAACTGGAACTGGCGGAA 
321        T  K  A  L  T  D  I  V  P  L  T  E  E  A  E  L  E  L  A  E   
 
1021      AACCGCGAAATTCTGAAAGAACCTGTGCACGGCGTCTATTATGATCCGAGCAAAGATCTG 
341        N  R  E  I  L  K  E  P  V  H  G  V  Y  Y  D  P  S  K  D  L   
 
1081      ATTGCGGAAATCCAGAAACAGGGCGATGACCAGTGGACCTATCAGATCTATCAGGAACCG 
361        I  A  E  I  Q  K  Q  G  D  D  Q  W  T  Y  Q  I  Y  Q  E  P   
 
1141      TTTAAAAACCTGAAAACCGGCAAATATGCGAAACGTCGCACCACCCATACCAACGATGTG 
381        F  K  N  L  K  T  G  K  Y  A  K  R  R  T  T  H  T  N  D  V   
 
1201      AAACAACTGACCGAAGCGGTGCAGAAAATCAGCCTGGAAAGCATTGTGACCTGGGGCAAA 
401        K  Q  L  T  E  A  V  Q  K  I  S  L  E  S  I  V  T  W  G  K   
 
1261      ACCCCGAAATTTCGCCTGCCGATCCAGAAAGAAACCTGGGAAATCTGGTGGACCGATTAT 
421        T  P  K  F  R  L  P I  Q  K  E  T  W  E  I  W  W  T  D  Y   
 
1321      TGGCAGGCGACCTGGATTCCGGAATGGGAATTTGTTAATACCCCGCCGCTGGTGAAACTG 
441        W  Q  A  T  W  I  P  E  W  E  F  V  N  T  P  P  L  V  K  L   
 
1381      TGGTATCAACTGGAAAAAGAACCGATTGCGGGCGCGGAAACGTTCCATGCATAA 
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